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 Chapter 1  
Principles of Inhalation Therapy 
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1.      Introduction 
 
There are several ways to administer medication to patients. Since the 
early seventies drug delivery via inhalation has become the most important 
way of administration in pulmonary diseases such as asthma. Various aerosol 
delivery systems have been developed to this end, for use in adults, and only 
later modified for use in children. This is why much is known about 
inhalation therapy in adults, and only little about its use in young children 
(1). The studies presented in this thesis, therefore, mainly focused on 
inhalation therapy applied to young children.  
 
This introductory provides the essential background information about 
inhalation therapy. This knowledge should enable the reader to better 
understand the aims and results of the studies presented in the next chapters. 
In addition, it highlights the key factors that influence efficiency and efficacy 
of inhalation therapy. Finally, an overview of radio-labeled deposition studies 
and clinical efficacy studies is given. 
2.     Inhalation Therapy 
Inhalation therapy, or aerosol therapy, can be described as the 
inhalation of an aerosol targeted at treating diseased areas of the respiratory 
tract. Inhalation therapy has been practiced since ancient times, when patients 
were recommended to breathe the fumes carrying sulfuric vapors from the 
slopes of the Vesuvius (2). Throughout the centuries, a variety of inhalation 
therapies – inhaling smoke of burning plants and the “asthma cigarette” 
(Figure 1) – have been used for therapeutic purposes (2, 3). It is through the 
development of devices designed to aerosolize medication that inhalation 
therapy has become the preferred method to treat respiratory diseases (4). 
Asthma and chronic obstructive pulmonary disease (COPD) used to be the 
major diseases treated by aerosol therapy. To these have now been added 
other respiratory diseases such as: bronchopulmonary dysplasia (BPD)(5, 6); 
cystic fibrosis (CF) (7-10); primary ciliary dyskenisia (PCD) (11, 12); 
chronic bacterial bronchitis; atelectasis (13-15); and laryngitis (croup) (16-
18). The most recent development is the introduction of inhalation therapy 
for non-respiratory diseases such as pulmonary hypertension, diabetes, and 
massive burn and smoke-inhalation injury (19-25). Furthermore, in 
vaccination campaigns the inhalation of aerosolized antigens is used as an 
alternative to subcutaneous injection (26-28). 
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Figure 1.  Asthma cigarettes (29) 
 
Inhalation therapy for pulmonary diseases has the advantage of direct 
delivery of the medication to its site of action. This should produce a more 
rapid therapeutic effect. Furthermore, less medication is needed to get the 
same therapeutic effect that systemically delivered medication would 
produce. As a consequence, inhalation therapy has a high efficacy/toxicity 
ratio (1, 3).  
 
A disadvantage of inhalation therapy, however, is its great complexity 
compared with systemic therapy. Firstly, the aerosolized drug is delivered to 
the lung, which is an organ specialized to exclude foreign material (1, 4). 
Secondly, many types of aerosol delivery devices are available, each with its 
own specifications and limitations. Knowledge of the various features is 
needed to select the most efficient device for a particular patient. Inhalation 
therapy in the pediatric age group is even more complex than in adults, as it 
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includes different patient categories in terms of anatomy and psychological 
developmental level (1). Each category, from neonates to teenagers, would 
therefore require a special approach.  
 
To achieve efficient and effective inhalation therapy, i.e. the highest 
efficacy/toxicity ratio, the first concern is to deliver the right amount of drug 
to the patient. The next concern is to have this amount of drug deposited at 
the right site of action in the lung (30). Furthermore, for successful inhalation 
therapy, the prescribing clinician should have knowledge of the properties, 
behaviors and physical principles of therapeutic aerosols, and of device- and 
patient-related factors influencing efficiency and efficacy. 
 
Figure 2 illustrates the different aspects of inhalation therapy. The 
numbers in this figure correspond to the following sections in this chapter in 
which they are discussed. 
3.     Aerosols 
An aerosol is a collection of solid or liquid particles suspended in a gas 
(3, 31). Dust, smoke, mist, fog, haze, and smog are examples of aerosols. 
Aerosol particles may vary in shape, size and density. Their description is 
simplified by the concept of aerodynamic diameter, i.e. the diameter of a 
sphere with a unit density that has aerodynamic behavior identical to that of 
the aerosol particle. Particles having the same aerodynamic diameter may 
have different dimensions, shapes, and densities (3, 31). The range of 
diameters of aerosol particles is between 0.01 and 100 µm. Particles larger 
than 100 µm normally do not remain suspended in air for a sufficient amount 
of time. In general, aerosols do not remain indefinitely stable in air.  
 
Therapeutic aerosols usually contain particles with a wide range of 
aerodynamic diameters and are then referred to as polydisperse aerosols. 
Polydisperse aerosols are described by their mass median aerodynamic 
diameter (MMAD) and their geometric standard deviation (GSD) (3). The 
MMAD is defined as the aerodynamic diameter for which half of the aerosol 
mass consists of larger particles and half the aerosol mass of smaller particles 
(3, 31, 32). The GSD describes the particle size distribution and is defined as 
the ratio of the diameter of the particle on the 84.2th percentile and the 
median diameter (3). A second type of aerosols, monodisperse aerosols, 
contain particles with a small range of aerodynamic diameters: the GSD is 
smaller than 1.2. The distinction between monodipserse and polydisperse is 
quite essential, as the lung deposition pattern of a polydisperse aerosol with a 
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certain MMAD may be different from that of a monodisperse aerosol with 
the same MMAD (3).  
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Figure 2. Overview of contents Chapter 1: Complexity of Inhalation Therapy. 
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Therapeutic aerosols with a MMAD ranging between 1 and 5 µm are 
believed to have the highest probability of deposition in the lower respiratory 
tract and are often referred to as respirable aerosols (Figure 3) (3). 
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Figure 3. In-vivo deposition of particles in the human airways. (33) based on ref. (34) 
(flow rate: 250 ml/s, tidal volume: 1000ml) 
 
In general, smaller particles have a higher likelihood of being 
deposited more peripherally than have larger particles. Particles larger than 
10 µm are less likely to enter the tracheobronchial tree. While particles 
between 0.1 µm and 1 µm have a higher probability to penetrate deep into the 
lung, they also have a higher probability to be exhaled. For particles smaller 
than 0.1 µm, deposition efficiency increases again due to diffusion (see 
section 5.1). 
4.     Aerosol Delivery Systems 
Aerosols are delivered to patients by means of aerosol delivery 
systems, of which many types are available. They are classified into three 
main categories: pressurized metered dose inhalers (pMDIs), dry powder 
inhalers (DPIs), and nebulizers (30, 32). The first category, the pMDIs, can 
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be further classified into two sub-categories, based on their operating 
technique: the breath-actuated method and the press-and-breath method with 
or without spacer. Most aerosol delivery devices were primarily designed for 
use in adults and subsequently modified for use in children. Nebulizers and 
pMDIs with spacers are currently the most efficient delivery systems for 
young children and are discussed in detail in this section. By contrast, DPIs 
and breath-actuated pMDIs are not used in young children and are, therefore, 
only briefly mentioned. 
 
 
 
(a) (b) 
 
Figure 4. Schematic cross-section of a pMDI (a) and detail of the container (b) (32). 
4.1      pMDI-Spacer 
Pressurized Metered Dose Inhaler 
Launched in 1956, the pMDI has since then become very popular 
because it is small, is noiseless during administration, and has a short 
administration time. Nowadays, it is the most frequently prescribed method 
for therapeutic aerosol delivery. The pMDI consists of a pressurized canister 
containing micronized drug, propellant, and surfactant (Figure 4). As the 
medication is usually suspended rather than dissolved in the propellant-
surfactant mixture, the pMDI must be shaken vigorously before use, so as to 
mix the medication with the propellant and surfactant (3, 35, 36). After 
shaking, the pMDI should be fired directly, seeing that the mixture of 
medication, propellant and surfactant will rapidly separate within the canister 
(3). The propellant in the mixture serves as the energy source for expelling 
the drug from the canister into the air. The surfactant reduces aggregation 
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within the chamber and lubricates the valve stem (3). The 
propellant/surfactant/medication mixture is released from the canister through 
the metering valve and the stem. The stem fits in an actuator boot designed 
and tested to work with that specific propellant/surfactant/medication mixture 
(35-37). As small changes in actuator design can substantially change the 
pMDIs aerosol characteristics and output, a canister should be used with a 
specifically designed actuator (35, 36). 
 
During actuation, the metering chamber is closed to the canister and 
open to the atmosphere. An aerosol cloud containing the 
propellant/surfactant/medication mixture leaves the actuator at high velocity. 
The released aerosol particles rapidly decelerate due to the resistance of the 
air and decrease in size as the propellant evaporates (3). If fired directly in the 
mouth, approximately 80% of the dose leaving the actuator will impact on the 
oropharynx due to the high velocity of the aerosol cloud (38). The dose 
deposited in the mouth may cause local side effects such as a candida 
infection (39). In addition, the drug will be swallowed and/or absorbed from 
the mucus of the oropharynx and may thus also contribute to systemic side 
effects (40-42). 
 
Until recently, chlorofluorocarbons (CFCs) were used as propellants in 
pMDIs. However, in accordance with the Montreal Protocol on Substances 
that Deplete the Ozone Layer, most CFCs have now been replaced with the 
more environment-friendly hydrofluoroalkanes (HFAs). The transition from 
CFCs to HFAs was used as an opportunity to improve pMDI technology. The 
first HFA-pMDI, containing salbutamol, had an adapted valve design that 
resulted in a more constant dose from the first to the last actuation. The dose 
having become less temperature-dependent as well, dose variability was 
further reduced (43). Furthermore, the lower velocity of the aerosol cloud 
traveling from the actuator reduced the oropharyngeal deposition due to 
lower impaction (see section 4.1.1) (44). HFA-pMDIs containing 
beclomethasone dipropionate (BDP) deliver aerosols with a MMAD of 1.1 
µm (45). These small particles are of particular relevance for aerosol therapy 
in young children. In a laboratory study using an upper-airway model of a 9-
month old child (SAINT-model), Janssens et al. showed that the HFA-BDP 
pMDI yields substantially higher lung doses than does the CFC-pMDI (46). 
Moreover, the large proportion of extra-fine particles in the HFA-BDP pMDI 
reduced the breathing pattern related variability in lung dose when compared 
with the CFC-pMDI (46).   
 
A problematic feature of pMDIs that are based on the press-and-breath 
method, is synchronizing the moment of dose actuation with time of 
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inhalation (32, 47, 48). To overcome this hand-breath coordination problem, 
a breath-actuated system was developed in the 1990s. This system makes it 
possible for the inspiratory flow rate to release a dose at the onset of an 
inhalation. Once the inspiratory flow rate exceeds 30 L/min, a vane is moved. 
This presses the canister in the actuator and subsequently the pMDI is fired. 
Although the breath-actuated system eliminates the coordination problem, it 
does not yet eliminate the high oropharyngeal deposition. In addition, the 
minimum flow rate presents a problem for young children, who generally 
will not be able to reach a flow rate of 30 L/min. Therefore, the breath-
actuated pMDI is not recommended for young children (35, 36). 
Spacers 
In the 1980s, attempts to overcome the problem of hand-breath 
coordination were made by developing so-called spacers (Figure 5) (49-52). 
In addition, spacers carry the advantage of substantially reducing the 
oropharyngeal deposition. Spacers allow the aerosol cloud to expand and the 
aerosol particles to decelerate and evaporate (36, 50, 53). In addition, coarse 
aerosol particles are likely to impact on the spacer’s inner surface. The dose 
inhaled from a spacer consequently contains a large proportion of fine 
particles (36, 54). In adults, the use of a pMDI-spacer combination improves 
the therapeutic effect by its improved efficiency of aerosol delivery (51, 52, 
54, 55). Radio-labeled studies in adults using a pMDI-spacer combination 
showed a lung deposition between 20 and 45% of the metered dose (56, 57). 
 
The pMDI-spacer combination is particularly useful in the treatment of 
children. Inspiration and expiration valves incorporated in the spacer enable 
inhalation with multiple breaths, which is of help to children who cannot 
clear the aerosol cloud from the spacer in a single inhalation. Low-resistance 
valves incorporated in the spacer even enable children with low tidal volumes 
to effectively open and close the valves (58). Importantly, for use in young 
children who are unable to breathe through a mouthpiece, the spacer should 
be fitted with a facemask. This would allow them to inhale the aerosol using 
tidal breathing (3, 35, 36, 59). In young children, nevertheless, the doses 
delivered to the lung by means of pMDI-spacer are still low. Radio-labeled 
studies in children younger than 4 years showed lung depositions between 
0.67% and 16.4% of metered doses (60-62). In children older than 8 years, 
lung deposition was 41.8% of the metered dose (60). Strong attempts should 
be made, therefore, to improve the efficiency of aerosol delivery in young 
children. 
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pMDI-Spacer Interaction 
Factors such as aerosol output, particle size distribution, and dose 
variability are determined by a variety of features related to the pMDI-spacer 
combination. These features are discussed below. 
 
(a) 
 
(b) 
Figure 5 Example of commercially available spacers in the Netherlands. (a): Spacers 
fitted with facemask. (b): Spacers with mouthpiece. 1 is NebuChamber® 
(AstraZeneca), 2 is Aerochamber plus® (Trudell Medical International), 3 is 
Babyhaler® (GlaxoSmithKline), 4 is Volumatic® (GlaxoSmithKline). 
 
Spacer Volume & Design 
 
Spacer volume determines aerosol dose and -concentration within the 
spacer. The use of a small volume spacer generally results in a high initial 
concentration of the actuated dose in the spacer, but also in high particle 
impaction on the spacer’s inner surface. The use of a large volume spacer is 
associated with less impaction, and consequently with a greater dose 
available for inhalation. Patients with large tidal volumes can easily clear the 
aerosol cloud from a large volume spacer. However, young children with low 
tidal volumes need more time to do so. During inhalation, the aerosol 
particles will sediment on the spacer’s inner surface. A small volume spacer 
will therefore be more efficient for young children with low tidal volumes, as 
it involves a shorter time for emptying the aerosol cloud (58).  
 
The shape of the aerosol cloud leaving the actuator is different for each 
pMDI. Therefore, both form and volume of the spacer will determine the 
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amount of aerosol particles deposited on the spacer’s inner surface (58, 63). 
In a controlled laboratory setting using the SAINT-model with the 
electrostatic charge of the spacer having been eliminated, lung dose was 
shown to be primarily affected by the pMDI and not by the type of spacer 
(64). 
 
Valves  
 
Adults with acute asthma have been shown to have expiratory flows 
that may be insufficient to close the valve of a spacer. If so, exhaled breath 
will re-enter and blow the remaining aerosol out off the spacer. This 
phenomenon has been claimed to contribute to the poor response sometimes 
observed when spacers are used in acute asthma (58, 65). For use in children, 
the valve incorporated in the spacer must be of low resistance and operate 
efficiently at low tidal volumes. Partially open or deformed valves are likely 
to significantly impair drug delivery, since aerosolized drug may be lost by 
impaction on the incompletely opened valve (Figure 6) (58).  
 
Dead Volume Space 
 
A large dead volume space between the mouthpiece or facemask and 
the inspiratory valves may substantially reduce spacer efficiency in young 
children. In an in-vitro study it was shown that adding a 50 ml dead volume 
space to the spacer halved the dose output from the spacer at a tidal volume 
of 50 ml (58).  
 
 
(a) 
 
(b) 
Figure 6. Aerochamber mask (a) Normally closed inspiratory valve with small, 
closed expiratory valve. (b) Deformed valve with missing expiratory valve. 
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Electrostatic Charge  
 
The inner surface of plastic spacers may show electrostatic charge. 
Attracting aerosol particles to the spacer wall, this could significantly reduce 
dose output (66). A metal spacer was developed, therefore, to overcome the 
problem of electrostatic charge (67, 68). The electrostatic charge of plastic 
spacers can be substantially reduced for about one week, however, by coating 
with household detergent (66, 69-71). Coating in practice involves washing 
the plastic spacer thoroughly with household detergent and leaving it to drip 
dry. Dose outputs of detergent-coated spacers have been shown to equal 
those of metal spacers (66). Storing plastic spacers in nylon or plastic bags 
will induce electrostatic charge, so this is best avoided.  
 
Residence Time  
 
Time between actuation and inhalation is defined as the residence time. 
During this time aerosol particles will sediment to the spacer’s inner surface. 
Long residence time is associated with a high amount of aerosol particles 
settling to the spacer’s inner surface, leaving few aerosol particles available 
for inhalation (70, 71). This effect will be stronger for electrostatically 
charged spacers, as the electrical field causes the aerosol particles to settle 
more rapidly (70, 71). 
 
Multiple Actuations  
 
Multiple actuations may substantially reduce the dose delivered to the 
patient, as it causes aerosol particles to merge into larger aggregates that will 
more easily impact onto the spacer’s inner surface (70, 71). In case more 
actuations are needed, each actuation should immediately be followed by 
inhalation of the dose. This procedure should be repeated until the prescribed 
number of doses has been inhaled. 
 
Facemask 
 
Several studies suggest that facemask design is important for the 
efficiency of drug delivery (66, 72, 73). A facemask should tightly fit to the 
face to avoid air leaks and to minimize dead space volume. Janssens et al. in 
a daily-life study observed that it is difficult to obtain and maintain a good 
seal between the mask and the face, especially in uncooperative young 
children (66). To date, the precise effects of facemask leak size and position 
on drug delivery efficiency have not yet been investigated. 
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Inhalation Technique  
 
The recommended technique for the use of a pMDI-spacer 
combination consists of the following steps: First, shake the pMDI-spacer 
combination for 10 seconds; Second, with the child sitting in an upright 
position, place the facemask on child’s face or the mouthpiece between the 
teeth; Third, actuate a single puff in the spacer within 5 seconds after 
shaking; Fourth, let the child quietly inhale for at least 15 seconds using tidal 
breathing. Repeat this procedure if more puffs are needed. Although this 
technique seems easy, it is prone to errors leading to unpredictable dose 
output (66). In order to optimize aerosol delivery, both patients and parents 
should be properly instructed in applying the recommended technique of 
inhalation devices. In addition, the inhalation technique should be regularly 
checked (36, 74). Medical and nursing staff, therefore, should have up-to-
date knowledge on proper inhalation techniques and the factors that influence 
aerosol delivery. 
 
Cooperation & Breathing Pattern  
 
An important determinant for efficient aerosol therapy to young 
children is the child’s degree of cooperation. Janssens et al. found that one-
third of children under the age of 2 years become distressed during aerosol 
administration, resulting in high dose variability and low dose output from a 
spacer (66). Children in distress have highly irregular breathing patterns, 
characterized by high inspiratory flow rates and long intervals between 
breaths. Studies using radio-labeled aerosols showed highly inefficient 
delivery of aerosols to crying or upset children (61, 75). Clinicians, therefore, 
have recommended aerosol administration during sleep, which in theory may 
be an interesting alternative. In a laboratory study, Janssens et al found lung 
deposition with sleep-breathing patterns to be significantly higher than that 
with wake-breathing patterns (76). However, the feasibility and efficacy of 
aerosol administration during sleep have not yet been studied in daily life. 
4.2      Nebulizers 
Types of nebulizers 
The nebulizer has been the mainstay of aerosol therapy for many years. 
However, with the development of other delivery systems, such as the pMDI, 
the nebulizer is no longer the first choice in the treatment of asthma. It is 
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nowadays mainly used to deliver medications, such as inhaled antibiotics, 
that are only available as fluids. Furthermore, the nebulizer is applied for 
delivering high doses of bronchodilators in case of acute asthma, or when 
other delivery systems are not well accepted by the patient (3). 
 
Two types of nebulizer systems are available, distinguished by 
principle of aerosol generation: the jet nebulizer and the ultrasonic nebulizer 
(Figure 7). The jet nebulizer uses a jet of compressed air, which is forced 
through a nozzle under high pressure. In the nozzle the air moves at high 
velocity (77). At the end of the nozzle, an abrupt decrease in pressure creates 
a vacuum, causing the drug solution to be driven through a narrow tube. 
Subsequently, the drug solution aerosolizes and long filaments are formed. 
These filaments break into droplets as a result of the effects of surface 
tension. Consequently, a wide range of aerosol droplet sizes is created (3, 
77). A baffle placed above the nozzle ensures that only smaller droplets can 
leave the nebulizer chamber. Most aerosol particles impact on the baffle and 
the chamber sidewalls, and subsequently fall back in the drug solution for re-
nebulization. Most nebulizer baffles are designed to ensure that the particle 
size distribution is in the range of 2-5 µm (3, 35, 77). 
 
 
(a) (b) 
Figure 7. Cross-section of : A. Jet nebulizer; B. Ultrasonic nebulizer (78) 
 
In the ultrasonic nebulizer, kinetic energy aerosolizes the drug 
solution. The kinetic energy is produced by a piezoelectric crystal that 
vibrates when a current is passed through (3). The frequency of the vibrating 
crystal determines the particle size of the droplets. Aerosol particles 
generated by the ultrasonic nebulizer are typically coarser than those 
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generated by the jet nebulizer (3, 77). Ultrasonic nebulizers are not suitable 
for suspensions, such as steroids, or for viscous fluids, such as antibiotics 
(79). The following section focuses on jet nebulizers, as these are most 
frequently used to treat children with pulmonary diseases. 
Interacting factors  
Various factors may affect the aerosol output and particle size 
distribution of a jet nebulizer.  
 
Driving airflow rate   
 
In jet nebulizers, the airflow rate through the nozzle determines droplet 
size and nebulization time. High flow rates (e.g. 8 L/min) result in smaller 
droplets and shorter nebulization times than do low flow rates (e.g. 4 L/min) 
(80). For many jet nebulizers a flow rate of 8 L/min is recommended (3, 77). 
 
Nebulizer design  
 
The design of the baffle is one of the determinants of nebulizer 
performance. The higher the fraction of aerosol particles intercepted by the 
baffle, the smaller the aerosol particle size but the longer the nebulization 
time (3, 77). In conventional jet nebulizers aerosol is continuously produced 
during inspiration and expiration. Continuous nebulization, however, wastes 
medication because aerosol generated during expiration is largely lost into 
the air (35). Modifications in jet nebulizer design have improved the 
efficiency of the nebulization process. Firstly, an open-vent system was 
developed, which allows additional air entrainment during inhalation causing 
a shorter nebulization time. However, open-vent systems are not efficient in 
young children, as their inspiratory flow rates do not exceed the output flow 
rate of the compressor (59, 81). Secondly, a breath-enhanced open-vent 
device was developed, which allows the patient to inhale additional air 
through an inspiratory vent. On exhalation, the inspiratory vent closes, and 
aerosol can only exit via a one-way valve near the mouthpiece. The breath-
enhanced open-vent device increases the amount of aerosol particles to 
inhale, without increasing the amount of aerosol particles lost during 
exhalation (35). Thirdly, a breath-actuated device was developed, which 
follows the patient’s breathing pattern. Nebulization takes place only during a 
predetermined fraction of the inspiration time. A breath-actuated device 
improves dose reproducibility and reduces loss of aerosol during exhalation. 
This improves the efficiency of drug delivery. However, using this device 
nebulization of the entire dose takes 3-4 times longer (delivering 3-4 times 
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more drug) than it does using a continuous operating jet nebulizer (35, 82, 
83). 
 
Fill volume and residual volume  
 
The residual volume is the volume of liquid that remains in the 
nebulizer after completion of nebulization. Residual volumes ranges from 0.5 
to 1.5 ml (35, 77). Consequently, at an initial small fill volume of 2 ml, more 
than 50% of the medication placed in the nebulizer will be retained. A larger 
fill volume gives a relatively smaller residual volume, allowing for a larger 
quantity of active medication to be nebulized (3).  
 
Fluid temperature  
 
In jet nebulizers, fluid temperature may drop approximately 7 °C 
during nebulization due to evaporation of the fluid. This temperature drop is 
associated with a decrease in particle size (84). In some ultrasonic nebulizers, 
fluid temperature may increase approximately 20 °C during nebulization. 
This is a potential problem for medication that is subject to denaturation, 
such as proteins(3, 35, 77).  
 
Physical properties of drug solution and suspension  
 
The viscosity of suspensions and solutions influences the rate of 
medication delivery. In case a jet nebulizer is used with a relatively low 
driving flow rate (6 L/min), the nebulization time for more viscous 
suspensions, such as antibiotics, can be relatively long. Hence, a driving flow 
rate of at least 8 L/min is generally recommended (3). 
 
Humidity and temperature  
 
High temperatures and relative humidity may give rise to hydroscopic 
growth of aerosol particles, i.e. an increase in particle diameter resulting from 
association with water vapor (85). When aerosol particles entrain into a warm 
and fully water-saturated air stream, they will increase in size. Additionally, 
they may coalesce and even further increase in size (35).   
 
Facemask 
 
It is of great importance that facemasks used in combination with a 
nebulizer are close-fitting. Keeping the facemask at a distance of 1 cm from 
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the face was found to halve the maximal inspired dose. At a distance of 2 cm, 
reduction amounted to 80% of the maximal inspired dose (86). 
 
Table 1. Advantages and disadvantages of aerosol delivery devices for use in 
children. Adapted from ref. (32) 
Device Advantages Disadvantages 
Nebulizer 
• Suitable for all ages 
• Tidal breathing possible 
• Delivery of high doses over 
prolonged period 
• Facemask can be used 
• Cumbersome 
• Noisy 
• Time consuming 
• Need of voltage supply 
• Risk of bacterial contamination 
• Poor reproducibility of dose and particle 
size 
• Large inter-device variability 
• Maintenance of compressor 
• Expensive 
pMDI 
• Small, handy 
• Quick 
• Low dose-to-dose variability 
• Complicated hand-mouth coordination 
• High oropharyngeal deposition caused by 
high velocity of aerosol  
• Not suitable for children 
pMDI 
 breath-actuated 
• Small, handy 
• Quick 
• No hand-mouth coordination 
required 
 
• High oropharyngeal deposition caused by 
high velocity of aerosol 
• Deep inspiration required 
• Not suitable for children younger than 7-8 
years 
• High inspiratory rate required 
pMDI/spacer 
• All ages 
• Tidal breathing possible  
• Facemask can be used 
• Quick 
• Reduced oropharyngeal 
deposition, and therefore less local 
side effects 
• Electrostatic charge of plastic spacers 
• Large size of spacer 
• Correct administration procedure is critical 
 
DPI 
• Small, handy 
• Quick 
• No hand-mouth coordination 
required 
• Propellant free 
• Reduced oropharyngeal 
deposition, and therefore less local 
side effects  
• High inspiratory flow rate required 
• Efficiency dependent on strength of patient 
• Not suitable for mostchildren younger than 
7-8 years 
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4.3     Advantages and disadvantages of aerosol delivery devices 
The advantages and disadvantages of the various aerosol delivery 
devices for use in children are presented in Fout! Verwijzingsbron niet 
gevonden. (32). Nebulizers and pMDI-spacers both have the advantage of 
facemask use, and require only tidal breathing. Therefore, patients of all ages 
can use these devices. An additional advantage of the pMDI-spacer over the 
nebulizer is that it is cheap, silent, small, time-efficient, and does not need 
power supply. On the other hand, the pMDI-spacer has a critical 
administration procedure: any deviation from the recommended procedure 
may increase dose variability and reduce the amount of medication available 
for inhalation (66). One advantage of nebulizers over pMDI-spacers is that a 
higher dose of medication can be nebulized. In addition, nebulizers can be 
used in combination with oxygen. Hence, in most emergency rooms 
nebulizers are the first choice in the treatment of an acute asthma attack (3).  
5.      Drug deposition in the lung 
Upon inhalation of an aerosol, particles may deposit anywhere within 
the respiratory tract or may be exhaled (3). Three factors influence the 
quantity of medication deposited in the lung and the distribution pattern of 
deposition: 
 
1. Physical properties of the aerosol; 
2. Physical deposition mechanisms; 
3. Patient-related mechanisms. 
 
Physical properties of the aerosol have been discussed in section 3. 
Physical deposition and patient-related mechanisms are discussed below. 
5.1     Physical deposition mechanisms 
Deposition of inhaled particles is primarily governed by three physical 
mechanisms: inertial impaction, sedimentation, and diffusion. The relative 
contribution of each mechanism is determined by the characteristics of the 
inhaled particles, and by patient-related mechanisms, such as breathing 
pattern and respiratory tract anatomy (30, 32). The impact of the three 
physical mechanisms on the lung deposition as function of particle size is 
shown in Figure 8. 
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Inertial impaction 
A parameter describing an airborne aerosol particle is the momentum. 
The momentum is the product of particle mass and particle velocity. Particles 
with large mass and/or large velocity have larger momentums. Upon changes 
in airflow direction, i.e. in the pharynx, the particle’s momentum determines 
whether the particle is able to follow the change in airflow direction or will 
impact onto the pharynx wall. The likelihood of impaction increases with 
increasing airflow rate and particle size. Impaction is the most important 
deposition mechanism in the upper and central airways and at or near 
bronchial bifurcations (Figure 9) (3, 30, 88). 
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Figure 8. Efficiencies of the particle deposition mechanisms of inertial impaction, 
sedimentation, and diffusion in relation to particle size (87). 
 
Sedimentation  
The total cross-sectional area of the more peripheral airways is 
substantially larger than that of the central airways. The flow, however, 
remains constant throughout the entire respiratory tract. The flow is defined 
as the product of cross-sectional area and flow rate. At a constant flow, 
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therefore, the flow rate in the peripheral airways is lower than that in the 
central airways (89). In peripheral airways, sedimentation is consequently the 
most likely deposition mechanism. Sedimentation is governed by 
gravitational forces and is a time-dependent process (Figure 10). The 
likelihood of sedimentation increases with residence time in the airway. For 
this reason, the breath-holding maneuver after inhalation increases the 
efficiency of lung deposition by means of sedimentation (3, 30, 89). 
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Figure 9. Inertial impaction. 
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Sedimentation and Inertial Impaction
Central Airways
Airflow
Impacting Particles
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Figure 10. Sedimentation and inertial impaction in the central airways. 
 
Diffusion and Brownian motion 
Diffusion is the primary transport mechanism for particles less than 0.1 
µm in diameter (Figure 8). When these particles are close to the airway wall, 
i.e. in the bronchioles and alveoli, diffusion is the most important mechanism 
of deposition. Collision of gas molecules with small aerosol particles in still 
air causes an irregular wiggling motion of the aerosol particles. This motion, 
called the Brownian motion, is the cause of the diffusion mechanism (Figure 
11). Diffusion of aerosol particles is defined as the net transport of these 
particles in a concentration gradient. This transport is always from a region of 
higher concentration to a region of lower concentration. For particles less 
than 0.05 µm, both diffusion and Brownian motion are characterized by the 
particle diffusion coefficient, which is inversely proportional to the particle 
size. For example, a 0.01 µm particle will be transported by diffusion 20.000 
times faster than a 10-µm particle (3, 30, 31). 
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Figure 11. Diffusion of aerosol particles in the peripheral airways. 
 
5.2     Patient-related mechanisms 
Quantities of particles deposited and site of deposition are influenced 
by the following patient-related factors: 
 
− Physiology of the airways (30, 35, 89-92); 
− Airway anatomy and pathology (90-94); 
− Breathing pattern, including frequency, flow rate, and tidal volume 
(30, 90, 91, 95-98). 
Airway physiology 
The respiratory tract includes defense mechanisms for the elimination 
of foreign material. For example, one of the functions of the nose is to filter 
particles. Deposition in the nose mainly results from impaction caused by 
turbulence occurring at the internal ostium (3). Hence, nasal filtration is 
greater for larger particles than it is for smaller particles. As young children 
are obligate nose breathers, they have a considerable chance of upper airway 
deposition (3, 30, 35, 90). 
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Airway anatomy and pathology 
Airway caliber is an important determinant of aerosol deposition. The 
mean airway lumen diameter of the respiratory tract between the main 
bronchi to the bronchioli increases two-threefold between birth and adulthood 
(90, 91, 99). The small airway caliber in infants and young children favors 
central airway deposition by impaction. In addition, lung pathology may 
further narrow small caliber airways (Figure 12) (90, 91, 99). Inflammation, 
edema, mucus, bronchoconstriction, and abnormal anatomy lead to changes 
in flow patterns and, consequently, in aerosol deposition patterns. Studies 
using radio-labeled aerosols have shown increased central deposition and 
reduced deposition in the peripheral airways in both adults and children with 
airway obstruction (61, 99-103). 
1. Tiddens, H. 2003. Facts and fiction in inhalation therapy. Ital J Pediatr 29:39-
43.
Adult Child Child with
inflammed airway
Figure 12. Deposition by impaction. While in healthy adults large particles may 
penetrate into the peripheral airways, in children with inflammatory lung disease 
only the smallest particle have a chance to penetrate into the peripheral airways (88). 
Breathing pattern 
The breathing pattern during aerosol inhalation greatly influences 
particle deposition in the respiratory tract (83, 91, 98, 104). A person’s 
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breathing pattern is characterized by factors such as flow rate and flow 
volume. Young children show a highly variable breathing pattern (Figure 13) 
(76, 83, 99). When crying, the child’s inspiratory flow rate will increase (75). 
High inspiratory flow rates, however, enhance the impaction of particles in 
the oropharynx and the central airways on account of a more turbulent 
airflow. This results in a lower lung deposition (75, 91). Furthermore, young 
children with low tidal volumes show reduced aerosol delivery, as they need 
more time to inhale the aerosol. During this time, aerosol particles tend to 
settle onto the spacer’s inner surface (58).  
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Figure 13. A young child’s typical breathing pattern (76). 
 
Older children and adults are able to inhale slowly and steadily, and to 
hold their breath for 5-10 seconds after inhalation. The slow and steady 
inhalation increases the fraction of inhaled particles that penetrates into the 
peripheral airways (30, 98, 104). A breath-holding period of 10 seconds after 
inhalation allows particles to be deposited by sedimentation (see section 5), 
and therefore, enhances peripheral lung deposition. Not being able to inhale 
slowly and steadily and to hold their breath, young children will generally 
inhale the administered aerosol by tidal breathing. Tidal breathing results in a 
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larger proportion of the inhaled aerosol being exhaled (58). Finally, the effect 
of breathing pattern on lung deposition cannot be seen separately from 
particle size. In an in-vitro study Janssens et al. showed that the lung dose of 
extra fine particles (MMAD <2.1 µm) was not associated with tidal volume, 
whereas the lung dose of particles between 2.1-4.7 µm decreased rapidly with 
increasing tidal volume (46). 
6.     Aerosol research in young children 
The previous sections discussed the many factors that influence the 
efficiency and efficacy of aerosol therapy. It was pointed out that many types 
of aerosol delivery devices are available, each with its particular 
characteristics that may influence aerosol therapy. These characteristics 
should be taken into account when opting for a device to be applied in the 
individual patient. We have to realize that data from studies in adults cannot 
be extrapolated to children, because children have different physiology, 
anatomy, pathology, and breathing patterns. Therefore, in order to optimize 
aerosol therapy in children, we need data from studies in children. This 
section presents a short overview of aerosol research methods and an 
overview of clinical efficacy and radio-labeled deposition studies in young 
children. 
6.1     Aerosol research methods 
The efficiency of aerosol therapy can be studied in-vitro or in-vivo. In-
vitro studies are useful to investigate factors that may influence the efficiency 
of aerosol delivery and to estimate lung deposition (105, 106).  
 
Pharmacokinetic, radio-labeled imaging, and clinical efficacy studies 
are examples of in-vivo studies. While the first two are used to quantify lung 
deposition (105, 107), clinical efficacy studies are used to evaluate the 
efficacy and safety of aerosol therapy (97, 108). 
In-vitro studies 
Impactors or laser diffraction systems are used to analyze an aerosol’s 
particle size distribution. Knowledge of particle size distribution is important 
for the development of new aerosol delivery devices. However, as in-vitro 
studies are known to overestimate the amount of drug reaching the lungs with 
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respect to the in-vivo situation (109), in-vitro studies are mainly used 
comparatively (105, 110).  
 
Upper airway models connected to computer-controlled breathing 
simulators are used to study factors that influence the efficiency of aerosol 
delivery devices. A filter placed between the device and the model measures 
the total dose delivered to the model at a certain breathing pattern. This 
method estimates total body deposition, but does not give information about 
the deposition pattern (46, 64, 76, 111).  
Pharmacokinetic studies 
In pharmacokinetic studies, lung deposition can be estimated by 
quantification of the amount of drug or metabolites in plasma or urine. Figure 
14 shows schematically what happens to an inhaled drug. In general, 
systemic drug levels represent drug absorbed via the lungs as well as via the 
gastrointestinal tract. They will, therefore, reflect only lung deposition when 
absorption via the gastrointestinal tract is prevented or when it is completely 
eliminated by the first-pass metabolism. Activated charcoal can be used to 
block the absorption from the gastrointestinal tract (41, 105, 113). 
Pharmacokinetic studies are of somewhat limited value in that they do not 
demonstrate regional lung deposition patterns (105, 113). 
Radio-labeled imaging studies 
Regional lung deposition pattern of inhaled aerosols can be assessed, 
nevertheless, by radionuclide imaging. Gamma scintigraphy, the most widely 
used imaging method, generates a 2-dimensional image (105, 107). Gamma 
scintigraphy uses drug formulations labeled with a radionucleotide, such as 
99mTc. After inhalation, these enable the lungs and oropharynx to be imaged 
in 2 dimensions by a gamma camera. The images distinguish lung zones 
representing the large, median and small airways, respectively. However, as 
the zones are arbitrarily demarcated, it is only possible to obtain an 
estimation of the deposition in the different zones. A more detailed 
deposition pattern can be provided by 3-dimensional imaging techniques, 
such as single photon emission computed tomography (SPECT) or positron 
emission tomography (PET) (106). 
 
These techniques are able to relate lung deposition patterns to different 
airway sizes with higher precision than does gamma scintigraphy. However, 
SPECT and PET are expensive and complex, requiring large quantities of 
radiotracers and long scanning times. In addition, they have not been 
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validated as adequately as the 2-dimensional gamma scintigraphy method 
(106). 
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Figure 14. Pharmacokinetics of inhaled drugs. After inhalation, the metered dose is 
partly deposited in the lung and partly deposited in the upper airways and 
subsequently swallowed. The systemic plasma concentration of an inhaled drug is the 
sum of the fraction absorbed directly from the lung and the fraction absorbed in the 
gastro-intestinal tract that is not eliminated by the first-pass metabolism. Based on 
ref. (112) 
Clinical efficacy studies 
Clinical efficacy studies may serve to test efficacy and safety of the 
inhalation therapy, provided they are designed as randomized, double-blind, 
placebo-controlled trials (114). Efficacy of bronchodilators is determined by 
lung function tests before and after inhalation of a bronchodilator. As 
bronchodilators show a rapid response after inhalation, reliable results can be 
obtained in small groups of patients. By contrast, a therapeutic effect of 
inhaled corticosteroids on chronic airway inflammation can not be measured 
until after 6 weeks (115-117). Consequently, measuring clinical efficacy of 
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inhaled corticosteroids demands long term studies with large numbers of 
patients, frequent lung function testing, registration of symptoms, hospital 
admissions, exacerbation, and concomitant administration of other drugs 
(32). 
6.2    Aerosol research in children 
Only few clinical efficacy and lung deposition studies in young 
children have been published. Most countries forbid lung deposition studies 
using radioactive aerosols in children for ethical reasons, as the long-term 
risks of high local deposition are still unknown. Table 2 gives an overview of 
the results of the available radio-labeled imaging studies in young children. 
Clinical efficacy studies in young children are few because it is difficult to 
make the diagnosis of asthma in children younger than 4 years. Furthermore, 
reproducible end-points that can be used to study large numbers of young 
children are lacking. Routine lung function testing is feasible in most children 
older than 6 years. Lung function testing in younger children is technically 
difficult and time consuming, and is restricted, therefore, to only a few 
centers.  
 
Recently developed, non-invasive methods to measure airway 
resistance and inflammation might be of help in aerosol research in young 
children. One of these, the respiratory resistance with the interrupter 
technique (Rint), enables to determine airway resistance during tidal 
breathing in children older than 3 years (118, 119). Another non-invasive 
method is the measurement of exhaled Nitric Oxide (eNO), which is a  
“surrogate marker” of airway inflammation (120-124). Both methods have 
recently been validated and reference values are now available (119). Seeking 
to improve aerosol therapy, several studies using eNO as an end-point were 
conducted in children older than 6 years (124, 125). To date, however, there 
is no evidence that eNO and Rint might be useful as end-points in clinical 
efficacy studies. Table 3 gives an overview of clinical efficacy studies in 
young children with recurrent wheeze. 
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Table 2. An overview of radio-labeled studies in young children 
Reference Age 
(range) 
 
Disease 
No. 
Subjects 
Aerosol 
Delivery device 
Lung 
deposition
Deposition 
expressed as 
Wildhaber(62) 2-4 yr Stable 
asthma 
8 Nebulizer and 
pMDI-AC (DC) 
5.4 % % of metered 
dose 
 
Wildhaber(60) < 4yr Stable 
asthma 
 
8 pMDI-BH (DC) 16.4 % % of total 
actuated 
dose 
 
Tal(61) 3 mo-
5yr 
7 asthma, 4 
CF, 4 BPD 
15 pMDI-AC (non-
DC) 
2% % of inhaled 
drug?? 
Amirav(101) 1-14 mo Acute RSV 12 Nebulizer 1.5 % in 
right lung 
% of 
nebulizer 
output 
 
Zar(126) 3-7 yr Stable 
asthma 
40 BH (DC) and AC 
(DC) 
using mouthpiece 
or facemask 
BH: 25% 
AC: 21% 
Use of 
facemask 
= 
Mouthpiec
e 
 
% of inhaled 
drug?? 
Mallol(102) 3-24 mo CF 20 Nebulizer 
using 2 different 
particle sizes 
0.97% % of total 
dose placed 
in nebulizer 
Chua(99) 4-15 mo CF 12 Nebulizer 1.3% % of 
nebulizer 
output 
AC: Aerochamber, BH: Babyhaler, DC: detergent-coated, CF: cystic fibrosis, BDP: 
bronchopulmonary dysplasia, RSV: respiratory syncytial virus 
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Table 3. Overview of clinical efficacy studies in young children with recurrent 
wheeze.  
Ref. Age  
(range) 
Subjects Design Duration Drug+Device End-points Outcome 
Barrueto 
(127) 
14-18 mo 31 
 
DB PC 8 weeks BDP/salb + AC (non-
DC) 
Symptom scores Symptom scores ∼ 
Bisgaard 
(128) 
11-36 mo 77 
 
DB parallel-
group 
12 weeks BUD + NH (non-DC)-
facemask 
Symptom scores Symptom scores ↑ 
Bisgaard 
(129) 
12-47 mo 625 
 
Parallel-group, 
open-label 
52 weeks FP + BH (DC?) / SCG 
+ NH (DC?) 
Symptom scores FP better efficacy  than 
SCG 
Bisgaard 
(130) 
12-47 mo 237 
 
DB PC 16 week FP + BH (non-DC) Symptom scores Symptom scores ↑ 
Chavasse 
(131) 
3-12 mo 48 
 
DB PC 2 months Salb + BH (non-DC) Diary cards + 
ILFT 
Vmax FRC  + symptom 
scores  ∼, increase in 
airway resistance 
Chavasse 
(132) 
3-12 mo 37 
 
DB PC 12 weeks FP + BH (DC?) -
facemask 
Symptom scores Symptom scores ↑ 
Conner 
(133) 
6-36 mo 25 DB PC 2 weeks Salb + AC (non-DC) Symtom scores Symptom scores ↑ 
Connet 
(134) 
1-3 yrs 26* DB PC 6 months BUD + NH (non-DC)-
facemask 
Symptom scores Symptom scores ↑ 
Hofhuis 
(135) 
6-22 mo 17 Retrospective  Terb + NH / Salb + 
BH 
ILFT Vmax FRC ∼ 
Hofhuis 
(136) 
4-24 mo 65 DB PC 16 weeks FP + BH (DC) -
facemask 
ILFT+ symptom 
scores 
Vmax FRC  + symptom 
scores ∼ 
Jackson 
(137) 
4-20 mo 16 
 
 1 day Albuterol + BH ILFT Airway resistance ∼ 
Kraemer 
(138) 
2-25 mo 29 
 
DB PC 6 week BDP/ Salb +BH (non-
DC) 
ILFT + symptom 
scores 
Lung function + 
symptom scores ↑ 
Noble 
(139) 
4 -18 mo 15 DB PC 6 weeks BUD + NH (non-DC) Symptom scores Symtom scores ↑ 
Mandelberg 
(140) 
10-48 mo 42** DB PC 1 day Salb + NC-facemask 
vs Salb + nebulizer 
RR, HR, PO 
clinical symptom 
measures 
Symptom scores ↑ Equal 
efficacy for 
NC and nebulizer 
Mellon 
(141) 
6-48 mo 214 
 
DB PC 12 weeks BUD + nebulizer-
facemask vs mouthpiece 
Symptoms scores Symptom scores ↑  
Equal efficacy for 
Facemask and mouthpiece 
Primhak 
(142) 
8-45 mo 33 
 
DB two-
period, four-
treatment 
 Salb + BH (non-DC)-
facemask 
Metacholine 
provocation test 
50-100 µg salbutamol is 
bronchoprotective 
Stick 
(143) 
5-18 mo 38 
 
DB PC 9 weeks BDP + NH  (non-DC) ILFT + symptom 
scores 
Vmax FRC + symptom 
scores ∼ 
Teper 
(144) 
7-24 mo 30 
 
DB PC 6 months FP + AC (DC) Symptom scores Symptom scores ↑ 
Van Bever 
(145) 
3-17  mo 23 
 
DB PC 10 weeks BUD + nebulizer Symptom scores Symptom scores ∼ 
Abbreviations: 
DB: double-blind. PC: placebo-controlled. BUD: budesonide. BDP: beclomethasone dipropionate. FP: 
fluticasone dipropionate. Salb: salbutamol. SCG: sodium cromoglycate. Terb: terbutaline.  AC: 
Aerochamber. BH: Babyhaler. NC: NebuChamber. NH: Nebuhaler. DC: detergent-coated. Non-DC: non-
detergent-coated. ILFT: Infant Lung Function Testing.  PO: pulse oximetry 
Symbols: 
*severe asthmatics 
** acute wheeze 
∼ : no significant improvement, ↑ : significant improvement 
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7.      Remarks 
A wide variety of factors that influence the efficiency and efficacy of 
inhalation therapy were discussed in this chapter. Mask design, cooperation 
and particle size seem to be the critical factors that affect inhalation therapy 
in young children. Many young children do not cooperate during aerosol 
administration, which makes it difficult to obtain a good seal of the mask on 
the face. In addition, crying during inhalation therapy gives high inspiratory 
flow rates, which result in high oropharyngeal deposition and low lung 
deposition. Moreover, obviously children have smaller airways than adults. 
They will, therefore, most likely benefit from smaller particle sizes, which 
most of the currently available devices unfortunately are not able to deliver. 
 
From a review of the literature it appears that the above factors have 
not been extensively investigated. Although many studies investigated the 
efficiency of aerosol therapy, only few concerned young patients. Detailed 
knowledge of these factors, however, is crucial to further optimize aerosol 
therapy in young children.  
8.     Aims and outline of this thesis 
The overall scope of this thesis is to contribute to the optimization of 
inhalation therapy in young children. The complexity of inhalation therapy in 
all its aspects was described in detail in the previous sections. One of the 
crucial factors for the efficiency of drug delivery to young children appeared 
to be the fit of the mask to the face (66, 73). In a daily life study using the 
pMDI-spacer combination, it was observed that obtaining and maintaining a 
good seal between the mask and the face is especially difficult in 
uncooperative young children (66). A few studies are available investigating 
the effect of facemask fit on drug delivery (72, 73, 146, 147). These studies, 
however, did not investigate whether and how size and position of the leak 
might affect the efficiency of drug delivery. We, therefore, set up an in-vitro 
study using the SAINT-model and a breathing simulator, aimed at 
investigating possible effects of size and position of a facemask leak on 
spacer output and lung dose (Chapter 2). Furthermore, in daily life study in 
young children using a spacer we examined how facemask design affects the 
efficiency of aerosol delivery (Chapter 3). 
 
A tight fit of the facemask is also important for the efficiency of drug 
delivery by means of a nebulizer (146). For nebulizers, a tightly fitted mask 
will minimize room air entrainment. The estimated maximal dose that is 
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likely to reach the patient, ranges between 11 and 14% of the nominal dose 
(148). A loosely fitted mask may cause adverse events due to exposure of the 
patient’s eyes and skin to the aerosolized drug (148). The current literature 
provides no information on patterns of aerosol loss associated with 
commercially available facemasks-nebulizer combinations. This is why we 
studied, from video-recordings, patterns of aerosol loss from various pediatric 
facemasks combined with a nebulizer (Chapter 4). 
 
Another important determinant for efficient aerosol therapy to young 
children is a child’s degree of cooperation. A daily life study found that one-
third of children under the age of 2 years become distressed during aerosol 
administration. This results in a high dose variability and a low dose output 
from a spacer (66). This is why administration of aerosols during sleep has 
been suggested as an alternative for uncooperative children (61, 76, 149). In 
Chapter 5, we present a study in which the feasibility of drug administration 
by means of pMDI-spacer in sleeping young children indeed was 
investigated. 
 
To achieve optimal efficacy of inhalation therapy, the aerosolized 
drugs should be delivered to the target regions in the lung. One of the factors 
influencing the efficacy of inhalation therapy is the particle size of the 
inhaled drug. To define the optimal particle size, clinical efficacy and 
systemic side effects of the inhaled drug should be determined (150, 151). 
Bronchodilators with a MMAD of 2.8 µm were shown to give the best 
improvement in lung function and the lowest systemic side effects in mild 
and severely affected asthmatic adults (150, 151). It is not known, however, 
whether inhaled steroids with a MMAD of 2.8 µm are also the most 
efficacious in asthmatic adults. To define the optimal particle size for inhaled 
corticosteroids, we set out to investigate the systemic absorption as function 
of aerosol size in adults with mild asthma, using monodisperse 
beclomethasone dipropionate (BDP) aerosols (Chapter 6).  
 
In Chapter 7, the results of the studies presented in this thesis are 
summarized and discussed, and suggestions for further research are proposed. 
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Abstract 
Aim: The objective of this investigation was to study the relation 
between size and position of a mask leak on spacer output and lung dose.  
Method: An upper-airway model (SAINT-model, Erasmus MC) was 
connected to a breathing simulator. Facemasks with leaks ranging between 0 
and 1.5 cm2 were examined. Leaks were located close to the nose or close to 
the chin. During simulated breathing, 200µg budesonide (Pulmicort®, 
AstraZeneca) was delivered to the model via NebuChamber® (AstraZeneca) 
with facemask. Spacer output and lung dose were measured by placing a 
filter between spacer and facemask or between model and breathing 
simulator, respectively. Budesonide trapped on the filter was quantified by 
means of HPLC, and expressed as % of the nominal dose.  
Results: Mean spacer output doses for the nose position were 50, 38, 
28, 12, 10, 6 and 0%, and for the chin position were 50, 40, 31, 11, 9, 4, and 
0% for leaks of 0, 0.05, 0.1, 0.16, 0.2, 0.3 and larger than 0.4 cm2, 
respectively. Mean lung doses for the nose position were 10, 8, 6, 3, 3, 1, 0, 
0, 0, 0%, and for the chin position were 10, 9, 8, 6, 6, 5, 1, 1, 0 and 0% for 
leaks of 0, 0.05, 0.1, 0.16, 0.2, 0.3, 0.4, 0.5, 1 and 1.5 cm2.  
Conclusions: Efficiency of a pMDI-spacer-facemask strongly depends 
on the size of a facemask leak. Spacer output did not depend on the position 
of the leak. Lung dose was higher for leaks near the chin than for leaks near 
the nose. 
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Introduction 
 
Over the past years, many inhalation devices have been developed to 
treat young children. The pMDI-spacer combination with a facemask is the 
first choice device for infants and young children.1,2 Clinical studies in young 
children have shown that many factors can affect the efficiency of the pMDI-
spacer-facemask.3-10 Factors like spacer volume, multiple actuations, 
electrostatic charge, breathing pattern of the child all influence the drug 
delivery to young children.3-10 In addition, it has been suggested that the fit of 
the mask to the face plays a role in the efficiency of drug delivery.1,3,10,11 In 
an in vivo study, it was observed, that it was difficult to obtain a tight 
facemask seal in non-cooperative children.3,10 There are only few studies 
performed in which the effect of the fit of the mask to the face on drug 
delivery was investigated.11-14 In an in vitro study, a 50% reduction in drug 
delivery was found when the mask of a nebulizer was removed 1 cm from the 
face.12 A distance of 2 cm from the face resulted in an 80% reduction in drug 
delivery. Recently, it was shown for both a nebulizer and a pMDI-spacer 
combination, that a leak between mask and face reduced drug delivery.14 
However, these studies did not investigate the relation between the size and 
position of the leak and the efficiency of drug delivery. The aim of our in 
vitro study was to investigate the relation between the size and position of a 
facemask leak on spacer output and lung dose. We hypothesized that, with an 
increase of the leak, less drug would be delivered to the patient and to the 
lungs. Furthermore, we hypothesized that the position of the leak would 
influence spacer output and lung dose.  
Materials & Methods 
Upper Airway Model 
The Sophia Anatomical Infant Nose-Throat (SAINT) model was used 
for aerosol deposition measurements. The SAINT-model is a CT scan-
derived, stereolithographically made, anatomically correct, and validated 
model of the upper airways of a 9-month-old infant.15 The model includes the 
face, nasal cavity, pharynx, and the subglottic region. The nasal airway is 
open for air passage; the oral airway is closed. To simulate sticky mucosa and 
to eliminate electrostatic charge, the inner surface of the model is coated with 
a thin layer of glycerol/Brij-35 (polyoxyethylene 23 laurylether) mixture  
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pMDI-spacer-facemask 
A budesonide pMDI, (Pulmicort 200µg, AstraZeneca, Sweden) in 
combination with a metal spacer (NebuChamber, AstraZeneca, Sweden) 
was used for the experiments. Before testing, a new pMDI was primed by 
shaking and firing 10 waste puffs. The NebuChamber was used in 
combination with a round-shaped resuscitation facemask (Galemed, 
Taiwan). A round facemask was chosen for practical reasons; it allowed us to 
create leaks of various sizes, which could easily be placed at different 
positions. Nine leaks ranging from 0.05, 0.1, 0.16, 0.2, 0.3, 0.4, 0.5, 1, to 1.5 
cm2 were drilled in the facemask (Fig. 1).     
 
 
     
Figure 1. Round-shaped resuscitation facemask (Galemed, Taiwan). Leaks of 
various sizes were drilled in the facemask.   
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Experimental set-up 
The SAINT-model was connected to a custom made computer-
controlled breathing simulator, which simulates infant breathing patterns16 
(Fig. 2). Filters (MQ303, Marquest®, USA) were used to collect the drug 
delivered from the pMDI-spacer-mask combination. For each measurement a 
new filter was used. Spacer output was measured by positioning the filter 
between the spacer and the facemask. Total lung dose was measured by 
positioning the filter between the SAINT-model and breathing simulator. 
Spacer output and lung doses are expressed as a percentage of the nominal 
dose. The influence of the position of the leak on spacer output and lung dose 
for different leak sizes was studied by placing the leak at the part of the mask 
placed over the nose (N) or at the part of the mask placed over the chin (C). 
Aerosol delivery was tested using a sinusoidal tidal breathing pattern, with a 
ratio of inspiratory time/total respiratory cycle time 0.42, tidal volume 100 
ml, and respiratory rate 30 breaths/minute. These settings are in accordance 
with the reference values appropriate for the age of the subject used to 
construct the model.17 The experiments were performed in ambient 
conditions with humidity of 30-40%. 
 
 
 
 
 
Figure 2. Experimental set-up to measure spacer output (A), and lung dose (B). Dose 
of drug is delivered by pMDI into a spacer/facemask and inhaled by the SAINT-
model connected to a breathing simulator. “Reprinted by permission from Ref.15.” 
| Facemask Leak    66  
Study procedure 
The SAINT-model was attached to the breathing simulator. Next, the 
pMDI-spacer with facemask was shaken and placed on the face of the model 
ensuring an airtight fit using therapeutic putty (Carters, Westbury, UK). 
Within 5 seconds after shaking, one puff of budesonide was actuated into the 
spacer, just before the start of an inspiration. Aerosol drawn from the spacer 
by the breathing simulator was trapped on a filter during 30 seconds of 
simulated tidal breathing. All measurements were repeated six times. After 
114 measurements the pMDI was replaced by a new pMDI.  
Drug analysis 
The drug trapped on the filter was analyzed at the laboratory of the 
department of Pharmacy of the Erasmus Medical Center Rotterdam. The 
budesonide on the filters was dissolved in ethanol containing an internal 
standard (fluocinolone acetonide). Budesonide was quantified by a validated 
High Performance Liquid Chromatography (HPLC) method, using an 
ethanol-water (43:57) mobile phase and a Supelcosil LC-18 column (5 µm 
particles, 5 * 0.46 cm (i.d.)). The coefficient of variation of this method was 
below 3%. Laboratory technicians were blinded for the experimental 
conditions of the filters.  
Statistical and data analysis 
The amount of budesonide on the filters is expressed as a percentage of 
the nominal dose. Results shown are means (±SEM). The data were 
linearised by plotting the logarithm of the mean spacer output or mean lung 
dose versus the leak size. Comparisons between spacer output and lung dose 
for different leaks and positions were tested using independent sample t-test. 
The following variables were tested: lung dose with a leak near the nose 
(LN), lung dose with a leak near the chin (LC), spacer output with a leak near 
the nose (SN), and spacer output with a leak near the chin (SC). The 
correlation between the leaks and these variables was investigated by using 
Pearson correlation coefficients (R). Analysis of covariance (ANCOVA) was 
performed to investigate the differences between the variables LN–LC and 
SN–SC. Regression analysis was used to fit the linearised data. Regression 
parameters were calculated at a confidence level of 95%. 
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Results 
Spacer output and lung doses for various leak sizes are shown in Table 
1. Spacer output (for SN and SC) correlated strongly to the increase of leak 
size (R=-0.99 and p< 0.0001) (Fig. 3A). Spacer output did not depend on the 
position of the leak. Lung dose versus leak size is shown in Figure 3B. Lung 
dose (for LN and LC) correlated strongly to the increase of the leak size (for 
LN R=-0.99 and p<0.0001, for LC R=-0.91 and p<0.0001). Lung dose was 
higher for leaks in the “Chin” position compared to the “Nose” position.  
Discussion 
In this study we investigated how size and position of a facemask leak 
influences spacer output and lung dose during tidal breathing. The study was 
conducted on an anatomically correct upper airway model of a nine-month-
old child. Both spacer output and lung dose decreased rapidly with increasing 
leak size. We showed that even a minor leak in the facemask was sufficient to 
reduce the lung dose by more than half compared to the lung dose obtained 
with a perfect mask seal.  
 
Table 1 - Spacer output doses with a leak near the nose (SN), and chin (SC), and lung 
doses with a leak near the nose (LN) and chin (LC). Results are means (± SEM) and 
expressed as % of the nominal dose.  
Leak (cm2) SN (%)  SC (%) LN (%) LC (%) 
0 50(4) 50(4) 10(2) 10(2) 
0.05 38(13) 40(6) 8(0) 9(1) 
0.1 28(3) 31(6) 6(1) 8(1) 
0.16 12(5) 11(3) 3(1) 6(2) 
0.2 10(3) 9(3) 3(1) 6(1) 
0.3 6(3) 4(4) 1(0) 5(1) 
0.4 0(0) 0(0) 0(0) 1(1) 
0.5 0(0) 0(0) 0(0) 1(1) 
1 0(0) 0(0) 0(0) 0(1) 
1.5 0(0) 0(0) 0(0) 0(0) 
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Figure 3. Part (a): Spacer output versus leak size. ـــــــــ hSN: leak is positioned close 
to the nose.---- o SC: leak is positioned close to the chin. Part (b): Lung dose versus 
leak size. ـــــــــhLN: leak is positioned close to the nose. ---- o LC: leak is positioned 
close to the chin 
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Our study confirms previous studies, that a good facemask-face seal is 
important for the efficiency of drug delivery.3,10-14 In a study with infants, it 
was observed that a poor facemask-face seal resulted in a low spacer 
output.3,10 However, the relation between facemask seal and drug delivery 
was not systematically investigated. Several facemasks in combination with 
the NebuChamber were studied in an in vivo filter-study in a “hospital 
setting.”11 The NebuChamber was attached to a data-logger, which measured 
the inhaled volume. The type of facemask attached to a spacer device was 
important for the volume inhaled from the spacer and consequently the dose 
of drug delivered to the child. In vitro studies investigating the influence of 
facemask seal on aerosol delivery showed that the amount of inhaled aerosol 
was decreased when a leak was present. However, the effect of size and 
position of the leak on lung dose was not investigated. 
 
To our knowledge, no systematic study on the relationship between 
leak size and drug delivery has been published. We found a strong negative 
correlation between the size of a leak and the lung dose. This result is 
especially relevant for inhalation therapy in children below the age of 2 years. 
Many of these children do not co-operate during the administration of a drug 
delivered by pMDI-spacer.2,3,6,9-11,18 In non-cooperative children, it is difficult 
to obtain a tight seal between the mask and the face. In case of an incomplete 
seal, it is likely that the amount of drug delivered to the child will be 
drastically reduced.  
 
Our study shows that not only the size, but also the position of the leak 
is important. Lung dose decreased more rapidly when the leak was positioned 
close to the nose relative to a leak located near the chin. However, spacer 
output did not differ for the nose or chin position. In the SAINT model used 
in the study, breathing is through the nose, as it is with most infants. A leak 
close to the nose may cause turbulence. Coarse particles are less able to 
follow turbulent airflow pattern and will impact on the face, inside the mask, 
or in the upper airways resulting in a reduction of lung dose.19,20 When the 
leak is located more distantly from the airflow coming from the spacer, the 
interference with the flow pattern will be less. This could explain why the 
lung dose/spacer output ratio increases with leak size. A technical study on 
the flow dynamics of the mask in relation to the position of the leak is needed 
to confirm our hypothesis. 
 
Clearly, our model study has its limitations. Firstly, spacer output dose 
only indicates the total dose delivered to the patient, and lung dose indicates 
the dose delivered beyond the subglottic level. They do not give any 
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information on the distribution of drug in the lower airways. Secondly, we 
used a round facemask instead of the original pre-shaped facemask of the 
NebuChamber. It is unlikely that the effect of leak size would be different for 
the pre-shaped NebuChamber mask. However, the effect of the position of 
the leak might be smaller since the dead volume of the NebuChamber mask is 
smaller. Thirdly, for purpose of standardization the shape and position of 
leaks in our study are different from those occurring in the every day 
administration procedures. However, it is likely that in real life any small 
leak between facemask and face will result in a similar reduction of lung dose 
as observed in our in vitro study.  
 
In conclusion, we showed that even a small air leak in the facemask 
can drastically reduce spacer output and lung dose. A leak close to the nose 
reduces lung dose more compared to a leak close to the chin. The results of 
this study stress the importance of a perfect seal between facemask and face 
when treating young children with a pMDI-spacer-facemask combination. 
Therefore, care should be taken that the mask has a good seal to the face, 
especially in the proximity of the nose. 
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Abstract 
Aim: This study aimed at identifying in a daily-life setting the 
influence of facemask design on drug delivery via a spacer to young children.   
Method: In a 4-week randomized crossover study, 24 children (7-23 
months old) with recurrent wheeze tested the AstraZeneca®, Galemed® and 
Hans Rudolph® facemask combined with the NebuChamber® at home. Each 
mask was tested twice daily for 7 consecutive days. Filters positioned 
between the NebuChamber and facemask trapped the budesonide aerosol 
(200 µg, Pulmicort®). Parents were asked to score the child’s degree of 
cooperation during administration on diary cards. The administration 
procedure was evaluated through video recordings. 
Results: Mean filter dose (standard deviation (s.d.)), expressed as % of 
nominal dose, was 39% (14), 47% (12) and 42% (11) for the AstraZeneca, 
the Galemed and the Hans Rudolph mask, respectively. Irrespective of the 
degree of cooperation, the Galemed mask gave significantly higher mean 
filter doses than the other masks (level of significance) (p < 0.045). Median 
(range) within-subject dose variability, expressed, as coefficient of variation 
(CV), was 37% (19-255), 32% (9-114) and 30% (9-115) for the AstraZeneca 
mask, the Galemed mask and the Hans Rudolph mask, respectively, not 
significant (ns). Dose variability increased with decreasing cooperation for all 
three masks (p = 0.007).  
Conclusions: Drug delivery to young children with recurrent wheeze 
by means of the NebuChamber can be enhanced using the Galemed 
facemask. Dose variability seems to be independent of facemask design but 
mainly depends on cooperation. 
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Introduction 
In infants and preschool children inhalation therapy with β2-agonist 
and corticosteroids can be effective in the treatment of recurrent wheeze (1-
6). The pressurized metered dose inhaler (pMDI)-spacer-facemask 
combination can be an efficient system to deliver aerosolized drug to young 
children. Efficiency, however, can be influenced by device-related factors – 
static charge, spacer volume, facemask design, and pMDI properties – and 
patient-related factors – breathing pattern, cooperation and administration 
technique (2, 4, 5, 7-11). 
 
Previous studies suggest that facemask design is important for the 
efficiency of drug delivery (11, 12). In a daily-life study we observed that 
obtaining and maintaining a good seal between the mask and the face is 
especially difficult in uncooperative young children (11). We found that dose 
delivery relates to the degree of cooperation for the NebuChamber® 
(AstraZeneca, Sweden) fitted with a face-shaped mask, but not for the 
detergent coated Babyhaler® (GlaxoWellcome, UK) with a round facemask. 
In this study, however, we did not systematically evaluate the relationship 
between facemask design and the efficiency of aerosol delivery. Therefore, 
we performed a daily-life study examining how facemask design affects the 
efficiency of aerosol delivery to young children by means of a spacer 
(NebuChamber). Furthermore, possible factors influencing filter dose and 
dose variability – like cooperation, inhalation technique, age, and symptoms 
– were studied. 
Materials and methods 
Study population 
Twenty-four children aged between 7 and 23 months, treated for 
recurrent wheeze with inhalation therapy twice daily, were recruited from the 
outpatient clinics of the Erasmus MC-Sophia (Rotterdam, the Netherlands), 
the Reinier de Graaf Gasthuis (Delft, the Netherlands) and the Albert 
Schweitzer Ziekenhuis (Dordrecht, the Netherlands). None of the subjects 
suffered from other disorders that could affect cooperation or lung function. 
Written informed consent was obtained from all parents. The Ethics Review 
Committee of Erasmus MC approved the study. 
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Study design 
In a 4-week randomized crossover study, we visited the children at 
home five times. Parents were asked to follow standardized instructions, 
which have been described previously (11), on the use of inhalation therapy. 
In addition, they were asked to administer the study medication before the 
child’s regular inhalation treatment, which was continued using their own 
medication and device. In a 1-week run-in period, the children practiced with 
three different masks (see Materials) in combination with the NebuChamber. 
In the following three study weeks, the children tested in randomized order 
each mask-NebuChamber combination twice daily for one week. Each week 
the children received a clean NebuChamber and facemask. To assess drug 
delivery, the parents were asked to place a new filter between the 
NebuChamber and the mask before each administration. For each child a 
maximum of 42 filters could thus be obtained.  
 
After every administration procedure parents were asked to fill out a 
diary card, evaluating cooperation and symptoms during the study period 
(11). Cooperation during administration was assigned a score ranging from 0 
(good cooperation) to 3 (fighting). The symptoms cough, wheeze and 
shortness of breath were each assigned a score ranging from 0 (no symptoms) 
to 4 (severe symptoms). The total symptom score, with a maximum of 12, 
was defined as the sum of the scores for cough, wheeze and shortness of 
breath. At the end of each study week, we recorded the administration 
procedure on video. Three observers scored in random order all video 
recordings, using a video checklist as described previously (11).   
Materials 
A pMDI (Pulmicort® 200µg, AstraZeneca, Sweden) delivered 
budesonide aerosol through the metal NebuChamber® (250 ml, AstraZeneca, 
Sweden) in combination with three different masks: the original facemask of 
the NebuChamber, hereafter called the AstraZeneca mask, the Galemed® 
(Galemed Corporation, Taiwan) facemask and the Hans Rudolph® (Hans 
Rudolph, inc., USA) facemask (Fig. 1). The face-shaped AstraZeneca mask 
has a thin and rather stiff rim. The round Galemed mask has a thick and 
flexible rim. The face-shaped Hans Rudolph mask has a thick rim and a flap 
to stabilize the mask on the chin. A plastic adapter was used to fit the Hans 
Rudolph mask onto the NebuChamber.  
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Each child received a new budesonide pMDI, primed by shaking and 
firing 10 waste puffs. A filter (Marquest®, MQ303, USA) inserted between 
the spacer and the facemask trapped the aerosol discharged by the spacer. 
The filter holders fitted tightly to the mouthpiece of the Nebuchamber. The 
filter holder of a Marquest filter added 38 ml of dead space. The pressure 
drop over the filter is 230 Pa at 60 L/min (13). 
 
 
Figure 1.  A. The AstraZeneca mask  B. The Galemed mask  C. The Hans Rudolph 
mask  
Filter analysis 
 All filters were analyzed in a blinded fashion at the laboratory of the 
Erasmus MC department of Hospital Pharmacy (Rotterdam, the Netherlands). 
The filters were washed with ethanol containing an internal standard 
(fluocinolone acetonide). Budesonide amounts were measured by high 
performance liquid chromatography (HPLC), using an ethanol-water (43:57) 
mobile phase and a Supelcosil LC-18 column (5 µm particles, 5 * 0.46 cm 
(inner diameter)). Budesonide was detected by UV-spectrophotometry at a 
wavelength of 254 nm. The coefficient of variation of the method was < 3%. 
Statistical analysis 
SPSS for Windows version 9.0 and SAS were used for statistical 
analyses. Filter dose, calculated as the amount of budesonide deposited on the 
filter, was expressed as a percentage of the nominal dose. The filter dose 
variability was expressed as the within-subject coefficient of variation (CV). 
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Study week sessions that yielded less than 3 filters, either in the morning 
sessions or in the evening sessions, were excluded from analysis. 
 
The mean (± SD) filter doses of the 14 samples collected each week 
was calculated for each child. T-tests were carried out to compare mean filter 
doses for each mask, after ensuring that the results were normally distributed. 
Wilcoxon’s signed rank test was used to compare the CVs for the three 
masks. Relationships between filter dose and age, filter dose and cooperation 
score, filter dose variability and age, and filter dose variability and 
cooperation score were assessed using Spearman’s correlation coefficient (r) 
and Repeated Measurements ANOVA (SAS PROC MIXED). Mean total 
symptom scores and mean cooperation scores obtained from the weekly diary 
cards were compared using the Friedman test. A p-value of ≤ 0.05 (two-
sided) was considered to indicate significant differences. 
 
Items on the video checklist relating to the child’s cooperation, i.e. 
“Child breathes for at least 15 seconds through the facemask from the start of 
the administration” and “Child breathes quietly through the facemask from 
the start of the administration”, were correlated with the filter dose obtained 
while the video recording took place, using Repeated Measurements 
ANOVA. 
Results 
Twenty-five children were enrolled into the study. One dropped out 
after the run-in period because of non-compliant parents. Twenty-four 
children (18 boys) completed the study. Median (range) age was 15 (7-23) 
months. Inhalation devices used before study entry were: NebuChamber 
(n=6), Babyhaler (n=9), AeroChamber® (Trudell Medicals, London, Ontario, 
Canada) (n=8) and nebulizer (n=1). A total of 285, 289 and 295 filters were 
collected for the AstraZeneca facemask, the Galemed facemask and the Hans 
Rudolph facemask, respectively. Only 5 (3.5%) of the total number of 144 
week-sessions were excluded from analysis because less than 3 morning or 
evening filters were collected.  
Filter dose 
Mean filter dose (SD) was 39% (14), 47% (12) and 42% (11) for the 
AstraZeneca mask, the Galemed mask and the Hans Rudolph mask, 
respectively. Mean filter dose of the Galemed mask was significantly higher 
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than that of the AstraZeneca mask (p=0.003) and the Hans Rudolph mask 
(p=0.045). The AstraZeneca mask and the Hans Rudolph mask did not 
significantly differ in mean filter dose. Simultaneous evaluation of masks and 
cooperation scores showed significant differences between the AstraZeneca 
mask and the Galemed mask and between the Galemed mask and the Hans 
Rudolph mask for both good/moderate cooperation (score 0 and 1) and poor 
cooperation (score 2 and 3) (Figure 2). For good/moderate cooperation, mean 
filter dose (SD) was 43% (12), 49% (11), and 44% (9) for the AstraZeneca 
mask, the Galemed mask and the Hans Rudolph mask, respectively. For poor 
cooperation, mean filter dose (SD) was 32% (17), 45% (14), and 38% (13) 
for the AstraZeneca mask, the Galemed mask and the Hans Rudolph mask, 
respectively. Children showing good/ moderate cooperation had on average a 
4.5% higher filter dose (p= 0.03) than children showing poor cooperation. 
However, the differences between the masks were not significantly different 
for the good/moderately cooperative children compared to the poorly 
cooperative children. Furthermore, the difference between good/moderate 
and poor cooperation for the AstraZeneca mask was not significantly 
different from the difference in cooperation score for the Galemed and Hans 
Rudolph mask. Filter dose did not correlate with age for any of the three 
masks. 
 
 
Figure 2. Mean filter doses expressed as percentage of the nominal dose (± SEM) 
for children with good/moderate cooperation (□) and with poor cooperation (●) for 
the AstraZeneca, the Galemed, and the Hans Rudolph masks. 
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Filter dose variability 
Median (range) filter dose variability was 37% (19-255), 32% (9-114) 
and 30% (9-115) for the AstraZeneca mask, the Galemed mask and the Hans 
Rudolph mask, respectively (ns). The AstraZeneca mask and the Galemed 
mask showed a significant positive correlation between the filter dose 
variability and the cooperation score (p<0.02). The slopes of the regression 
curves of filter dose variability versus the cooperation score were not 
significantly different (figure 3). The slope of pooled data from the three 
masks showed a significant positive relation (p=0.007). An increase of 1 
point on the cooperation scale (worse cooperation) led to a 32% increase in 
filter dose variability. Filter dose variability showed a negative correlation 
with age only for the Hans Rudolph mask (r=-0.5, p=0.01).  
 
 
Figure 3. Scatter plot of the filter dose variability (CV%) on a logarithmic scale 
versus cooperation score for the AstraZeneca, the Galemed, and the Hans Rudolph 
masks. ——, □ AstraZeneca mask; ·····, × Galemed mask; ----, ∆ Hans Rudolph 
mask. 
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Symptom and cooperation scores 
Median (range) symptom scores for the AstraZeneca mask, the 
Galemed mask and the Hans Rudolph mask were 0.2 (0-9), 0.5 (0-8) and 1.3 
(0-10), respectively (ns). 
 
 
Median cooperation score was 1.1, 0.9 and 1.1 for the AstraZeneca 
mask, the Galemed mask and the Hans Rudolph mask, respectively (ns). Poor 
cooperation (score 2 or 3) during the administration procedure was assigned 
in 28%, 33% and 36% of all scores for the AstraZeneca mask, the Galemed 
mask and the Hans Rudolph mask, respectively.  
Video recordings 
Children breathing at least 15 seconds through the facemask from the 
start of administration had significantly higher filter doses (p<0.03). Filter 
doses of children breathing quietly during administration did not differ from 
that of children crying during administration. 
Discussion 
This daily-life study was carried out to examine the influence of 
facemask design on the efficiency of aerosol delivery by means of the 
NebuChamber to young children with recurrent wheeze. We found that the 
round facemask (Galemed) gave a significantly higher filter dose than the 
pre-shaped facemasks (AstraZeneca and Hans Rudolph).  
 
Few studies have suggested that facemask design affects the efficiency 
of aerosol delivery (11, 12). However, the systematic evaluation of the 
relationship between facemask design and efficiency of aerosol delivery in 
daily life has only been attempted by Amirav et al (14). They found filter 
doses (as % of the nominal dose) of 28.1% and 21.6% for a round facemask 
and the AstraZeneca facemask, respectively (14). Although, the magnitude of 
difference between the round facemask and the AstraZeneca mask in this 
study is similar to ours, it is striking that mean filter doses in Amirav's study 
are less than half of the filter doses found in our study and previous filter 
studies (7, 11, 15, 16). The filter dose for the round mask in Amirav's study 
was even lower than the lowest filter dose in our study. Differences in the 
mean filter doses between Amirav's study and our study can be explained by 
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the differences in study design. In Amirav's study the observational period 
started immediately after instruction. In contrast, in our study subjects 
practised one week with the spacer, masks and the filter method before they 
were randomised, such that learning effects were reduced. In addition, in 
Amirav's study subjects inhaled once daily two puffs, whereas our study 
subjects inhaled twice daily one puff. As a result we collected not only twice 
as many filters for each subject, but most likely fewer mistakes per 
administration procedure were made because of the single-puff-dosing (4, 8, 
17).  
  
As suggested previously by other authors, our study supports the view 
that patient-related factors are important for the efficiency of aerosol delivery 
(7, 11, 18, 19). Moreover, in children younger than 2 years patient-factors, 
such as cooperation, are probably more important than facemask design. 
Young children often fight the administration procedure, such that it is 
difficult to obtain and maintain a complete facemask seal (7, 11, 20). Since 
our in-vitro work showed that even a small leak dramatically reduces filter 
dose, the significantly lower filter doses in uncooperative children can be 
explained by the incomplete seal (21). The uncooperative children had 
significantly lower filter doses for all masks, and the differences in filter 
doses between the masks did not relate to cooperation. Hence, we may 
conclude that, independent of the facemask design, it is difficult to obtain a 
tight seal when the child is uncooperative. We also found that the dose 
variability increased significantly when a child did not cooperate. However, 
we did not find significant differences between the filter dose variability of 
the different masks, while we expected that the filter dose variability would 
be highest for the mask with the lowest filter dose. Furthermore, we did not 
find a difference in cooperation score between the masks. It is, therefore, 
unlikely that facemask design influences cooperation. Clearly, many young 
children do not like to have any mask pressed on their face.  
 
In this study, the filter dose represents the total amount of aerosol 
delivered to the patient. It does not provide information on lung deposition or 
clinical efficacy. Lung dose depends on various patient-related factors, such 
as airway anatomy and breathing pattern. In the video analysis we showed 
that mean filter dose of children breathing quietly during administration was 
not significantly different from that of children crying during administration. 
Although the mean filter dose was similar, lung dose in crying children will 
be very low, since most of the drug delivered to the patient will be deposited 
in the oropharynx (9). In cooperative children, however, it is likely that a 
higher percentage of the drug delivered to the patient will be deposited in the 
lung.   
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In conclusion, the efficiency of aerosol delivery can be improved using 
a round facemask. However, whether this improvement in delivery efficiency 
is clinically relevant can only be determined by clinical efficacy studies (22). 
Since such a high percentage of young children are fighting the aerosol 
administration and these children do not easily accept any mask on their face, 
we should focus more on the improvement in acceptability of aerosol therapy 
in young children. 
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Abstract 
Most nebulizers have a loose fitted facemask. Even when the mask is 
placed tightly to the face, aerosol loss can be observed. This aerosol loss may 
cause local side effects due to exposure of the eyes and skin of the patient to 
aerosolized drug.  
Aim: To assess, by recording on video, the amount and the pattern of 
aerosol loss from various nebulizer-facemask combinations.  
Methods: In a randomized cross-over study, 33 children below 4 years 
of age were recorded on video during nebulization. Four commercially 
available nebulizer-facemask combinations were tested. Four observers 
scored randomly the videos using a checklist. Aerosol loss was scored 1 
(=none), 2 (= a little) or 3 (= a lot).  
Results: 93 videos were available for analysis. For the analysis of 
aerosol loss, there was a good level of agreement between the 4 observers 
(mean intra-class correlation coefficient > 0.69). The mean (± SD) score for 
aerosol loss was 1.7 (0.37), 1.4 (0.25), 2.1 (0.34) and 1.4 (0.28), for the Pari 
"Bubbles the FishTM", the Pari BabyTM Size 2, Hudson Neb-U-Mask, and 
the Salter, vented facemask with flaps, respectively. Aerosol loss of the 
Hudson Neb-U-Mask was significant higher compared with the other tested 
masks (p< 0.03). Large quantities of aerosol from the Hudson Neb-U-Mask 
were directed towards the eyes. Aerosol loss from the other three masks did 
not show a preferred direction.  
Conclusion: The Hudson Neb-U-Mask is likely to give a higher 
chance of local side effects due to a higher aerosol loss during nebulization 
compared with three other tested masks. 
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Introduction 
Inhalation therapy is a common treatment for respiratory diseases such 
as asthma and cystic fibrosis. Aerosolized medication is delivered to young 
children by using nebulizers and pressurized Metered-Dose Inhaler (pMDI)-
spacers combinations. Although nebulizers are noisy, cumbersome, 
expensive and time-consuming, they have the advantage of nebulizing most 
drugs, even as drug cocktails, in high doses (1-4). Furthermore, nebulizers are 
used in children who do not tolerate pMDI-spacers (4-8). 
 
In general, young children will not be able to use specific breathing 
techniques (9). They need a facemask for delivering aerosolized drug during 
tidal breathing. Efficient drug delivery with nebulizers is thought to benefit 
from tight fit of the facemask. In an in-vitro study, Everard et al. showed that 
distancing the nebulizer mask 1 cm from the child’s face, halved the inspired 
dose of medication. A distance of 2 cm even resulted in 80% dose reduction 
(8). Many nebulizers have loose fitting masks with open vents (10). In 
addition, aerosol loss through these vents may cause side effects, because the 
patient’s eyes and the skin are exposed to the nebulized drug. For example, 
for nebulized steroids, it has been suggested that such exposure may induce a 
steroid rash over the face, and may even include a risk for cataract (1, 11, 12).  
 
To date, there is no information available about patterns of aerosol loss 
using commercially available facemasks-nebulizer combinations in young 
children. Therefore, we aimed to assess, by video recording, patterns of 
aerosol loss from various facemasks combined with a nebulizer in young 
children. 
Methods & Materials 
Study population 
Children younger than 4 years treated with inhalation therapy were 
recruited from the outpatient clinic of the pediatric pulmonology department 
in the Erasmus MC-Sophia Children’s Hospital, the Netherlands. Those 
whose parents or legal guardians could not obtain a tight fit of the mask on 
the face during nebulization were then excluded. The study procedure was 
stopped if a child actively resisted the administration procedure. Written 
informed consent was obtained from all parents or legal guardians. The 
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National Ethics Committee (CCMO, The Hague, The Netherlands) approved 
the study. 
 
 
 
 
  
 
 
Figure 1. The four tested masks. Arrows indicate the position of the vents. A. Pari 
"Bubbles the FishTM" B. Pari BabyTM Size 2 C. Hudson Neb-U-Mask D. Salter, 
vented facemask with flaps. 
D 
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Materials 
The four nebulizer-facemask combinations used in this study are listed 
in Table 1. Vents positions for each mask are shown in Figure 1. The Pari LC 
Plus was combined with a Baby bend connection piece to attach the facemask 
to the nebulizer. All nebulizers were run using a PRONEB-Turbo compressor 
(Pari Respiratory Equipment, Inc., USA). Four ml of sterile Sodium chloride 
0.9% was used for nebulization. New facemasks and nebulizers were used for 
each child. 
 
Table 1. Nebulizer-facemask combinations 
Facemask Nebulizer 
Pari "Bubbles the FishTM"1 Pari LC Plus4  
Pari BabyTM Size 21 Pari LC Plus4 
Hudson Neb-U-Mask2 Hudson T-Updraft II2 
Salter, vented facemask with flaps3 Hudson T-Updraft II2 
1 Pari Respiratory Equipment, Inc., Montgomery, CA 
2 Hudson Respiratory Care, Inc., Temecula, CA 
3 Salter Labs. Arvin, CA 
4 PARI Respiratory Equipment, Inc., Germany 
Study design 
In this randomized, cross-over study, each child was to test all 4 
facemask-nebulizer combinations (Table 1). Figure 2 shows the experimental 
set-up. During aerosol administration, the child sat in the lap of an elder and 
was encouraged to sit as quiet as possible, while its favorite music played. 
Overall room light was dimmed and four specially designed lamps placed at 
both sides of the child were switched on for optimal visualization of the 
aerosol cloud. A digital camera (Sony, DCR-VX 1000, Sony Corporation, 
Japan) recorded the administration procedures from a frontal view for 90 
seconds. Camera distance and settings were standardized.  
Video analysis 
After completion of the study all recordings were edited to show only 
episodes of active nebulization. Subsequently, 4 trained observers randomly 
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scored all edited recordings using a checklist including 4 items: 1. Visibility 
of the aerosol cloud; 2. Cooperation of the child; 3. Breathing pattern of the 
child; 4. Pattern of aerosol loss.  
 
The first 3 items were scored to assess recording quality and suitability 
for analysis using a three-point scale: 1 = not at all; 2 = bad; or 3 = good. The 
end-point of the study, item 4, was scored using Figure 3, a four–quadrant 
division of the face. Aerosol loss in the quadrants was rated on a three-point 
scale: 1 = none; 2 = little; and 3 = a lot.  
 
Each observer independently scored all recordings. Agreement 
between the observers was assessed by calculation of the kappa coefficient. 
Recordings were excluded for statistical analysis if the child did not comply 
with the protocol or when the aerosol cloud could not be visualized. 
 
Light
Digital Video
Camera
Aerosol Cloud
Facemask
Figure 2. Experimental set-up, the child sits in the lap of the parent. Four 
specially designed lamps light the child’s face, and visualize the aerosol 
cloud. 
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Statistics 
SPSS for Windows version 10.1 was used for statistical analysis. Mean 
values of the 4 observers were used in the evaluation of the aerosol loss. 
Paired comparisons between the 4 masks were done using Wilcoxon’s Signed 
Ranking tests. These tests were also used to compare aerosol loss for the 4 
quadrants (Figure 3) within the mask. 
 
 
 
 
 Not at all Bad Good 
1. Good visible aerosol cloud    
2. Cooperative child    
3. Quiet breathing    
4. Aerosol loss in: 
Quadrant 1 
 None 
 Little 
 A lot 
                 Quadrant 2
                       None 
                       Little 
                       A lot 
 
 
 
Quadrant 3 
 None 
 Little 
 A lot 
                                  
                  
 
                 Quadrant 4  
                       None 
                       Little 
                       A lot 
 
Figure 3. Checklist for scoring the video recordings.  
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Results 
Thirty-three children were included in this study. Their characteristics 
are shown in Table 2.  
 
Five children were later excluded because the parents and/or the child 
could not comply with the protocol. Nine children could not test all 4 masks, 
since they refused further cooperation at some point: three of these children 
had tested 3 masks, two had tested 2 masks and four had tested 1 mask. 
Nineteen children completed the entire study. In total 93 video recordings 
were available for assessment. 
 
For assessment of aerosol loss, a good level of agreement between the 
4 observers was found (mean kappa coefficient > 0.69). Fourteen of the 93 
available videos appeared unsuitable for further statistical analysis, due to the 
child’s restlessness and/or bad visibility of the aerosol cloud.. 
Aerosol loss 
The mean total aerosol loss score was significantly higher for the 
Hudson Neb-U-Mask compared with the three other masks (p< 0.03). The 
mean (± SD) total aerosol loss score was 1.7 (0.37), 1.4 (0.25), 2.1 (0.34) and 
1.4 (0.28), for the Pari "Bubbles the FishTM", the Pari BabyTM Size 2, 
Hudson Neb-U-Mask, and the Salter, vented facemask with flaps, 
respectively. 
 
Table 3 shows the aerosol loss in the 4 quadrants for each mask.  For 
the Pari "Bubbles the FishTM" mask, highest loss was in quadrant 4. For the 
Hudson Neb-U-Mask, substantial aerosol loss was observed in quadrants 1 
and 2. Aerosol loss for the Pari BabyTM Size 2 mask and the Salter vented 
facemask was minimal, and there were no significant differences in aerosol 
loss between the quadrants. 
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Table 2. Patient characteristics 
Age (yrs) Sex Diagnosis Inhalation 
therapy history 
No. of masks tested No. of masks used for 
statistical analysis 
0.6 F CF Nebulizer 3 1 
0.6 M BPD PMDI-spacer 2 1 
0.7 M CF Nebulizer 4 2 
0.8 F Recurrent wheeze PMDI-spacer 3 2 
0.9 M CF Nebulizer 4 2 
1 F CF Nebulizer 4 4 
1 M CF Nebulizer 1 1 
1.5 F Recurrent wheeze PMDI-spacer 4 4 
1.5 F CF Nebulizer 4 4 
2 M CF Nebulizer 4 4 
2 M CF Nebulizer 4 4 
2 M Recurrent wheeze PMDI-spacer 1 0 
2 M Asthma PMDI-spacer + 4 4 
2 M Recurrent wheeze PMDI-spacer 4 4 
2 M Recurrent wheeze Nebulizer 4 3 
2.5 M CF Nebulizer 4 3 
2.5 F CF Nebulizer 0 0 
2.5 M Recurrent wheeze PMDI-spacer 4 4 
2.5 M Recurrent wheeze PMDI-spacer 1 0 
2.5 M Recurrent wheeze PMDI-spacer 0 0 
2.5 M Recurrent wheeze PMDI-spacer 0 0 
3 F CF Nebulizer 3 3 
3 M BPD Nebulizer 0 0 
3 M Recurrent wheeze PMDI-spacer 4 4 
3.5 F CF Nebulizer 2 2 
3.5 F CF Nebulizer 4 3 
3.5 F CF Nebulizer 1 0 
3.5 F CF Nebulizer 4 4 
3.5 F CF Nebulizer 4 4 
3.5 M Asthma PMDI-spacer + 4 4 
4 F CF Nebulizer 4 4 
4 M CF Nebulizer 0 0 
4 M CF Nebulizer 4 4 
+  PMDI-spacer plus nebulizer 
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Table 3. Aerosol loss scores over quadrants (range: 1= none; 2= a little; 3= a lot) 
 Quadrant 
Mask 1 2 3 4 
Pari "Bubbles the FishTM" 1.7 1.5 1.7 2.0* 
Pari BabyTM Size 2 1.3 1.4 1.3 1.5 
Hudson Neb-U-Mask 2.8* 2.9* 1.3 1.4 
Salter, vented facemask 
with flaps 
1.5 1.5 1.2 1.3 
Discussion 
During nebulization, young children are not able to use specific 
inhalation techniques (9). They, therefore, need a facemask to deliver 
aerosolized drug during tidal breathing. As most nebulizer masks fit loosely 
to the face and have open vents (10), aerosol will leak and aerosol delivery 
efficiency will be reduced. In addition, the patient’s eyes and the skin will be 
exposed to aerosolized drug. This aerosol exposure may cause local side 
effects (1, 11, 12). In our study, the Pari "Bubbles the FishTM", the Pari 
BabyTM Size 2, and the Salter facemask showed little total aerosol loss 
during nebulization. On the contrary, the Hudson Neb-U-Mask showed a 
significant higher total aerosol loss compared with the other three masks. 
Therefore, use of the Hudson Neb-U-Mask is associated with a higher risk of 
local side effects of nebulization therapy, compared with the other three 
masks. 
 
Although our study design indeed resulted in visualization of aerosol 
loss patterns, it is possible that the aerosol loss was not completely visualized 
on the video recordings. Lighting during recording is an important 
determinant of aerosol cloud image quality on video. An aerosol cloud is 
better visible when directly lighted. To this end, overall room light was 
uniformly dimmed and four specially designed lamps were focused on the 
patient in a standardized way. In addition, we included only children who 
were able to cooperate and sit quiet during nebulization. If children could not 
comply with these requirements, they were excluded for further analysis.  
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Another limitation of a video recording is that it gives a 2-dimensional 
image, providing for only a rough estimate of aerosol amounts spreading to 
the eyes and skin. Furthermore, we did not directly quantify doses deposited 
in the eyes and on the skin. However, the areas with the highest exposure to 
aerosol loss identified in our study will likely have the highest quantities of 
drug deposited on the face, and thus, will have the highest risk of local side 
effects. 
 
A more reliable method to quantify eyes and skin exposure during 
nebulization would probably be a radio-labeled study using a 3-dimensional 
imaging technique. For ethical reasons, however, radio-labeled studies are 
limited in the pediatric population (4, 13-18). In addition, 3-dimensional 
imaging techniques are complex and very expensive (19). 
 
Pattern of aerosol deposition in the eyes and on the face have 
previously been studied in-vitro using radio-labeled aerosols. A variety of 
facial and eye deposition patterns was found, depending on the nebulizer-
facemask combination (20). Facial deposition was significantly less when the 
facemask was vented. The authors suspected that differences in facial 
deposition patterns were related to the insertion point of the nebulizers into 
the mask. The results of our in-vivo study suggest that size and position of 
vents in the mask-nebulizer combination probably have higher impact on 
differences in aerosol loss patterns than the insertion point of the nebulizer in 
the facemask. We found that the Hudson Neb-U-Mask and the Salter mask, 
both used in combination with the Hudson T-Updraft nebulizer, showed 
significantly different patterns of aerosol loss. In addition, the pattern of 
aerosol loss from the Salter mask was actually not different from that of the 
Pari Baby 2, which was combined with the Pari LC Plus nebulizer. Our study 
showed that the Hudson Neb-U-Mask, a mask with large vents close to the 
face, exposes the child’s eyes and skin to large amounts of aerosol, especially 
during expiration. This effect can even be more dramatic in children under 
the age 2 years, as their inspiratory flow often does not exceed the driving 
flow of the nebulizer. In the youngest children, therefore, large amounts of 
aerosol can exit the mask-nebulizer combination even during inspiration (21). 
 
The side effects of aerosol deposition on the skin and in the eyes have 
not been extensively studied. From our study it is clear that a risk of potential 
side effects is present. Therefore, a mask with minimal risk of unwanted eye 
and skin exposure to aerosol should be selected for children. Masks with 
vents in the nebulizer itself or between the nebulizer and the facemask seem 
to be the best choice. These masks allow the extra aerosol to exit the 
nebulizer-facemask combination at a greater distance from the face.  
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In conclusion, in view of its higher total aerosol loss, use of the 
Hudson Neb-U-Mask in young children is associated with a higher risk of 
side effects to eyes and skin compared with the other tested masks. Masks 
with large vents close to the face are less suitable for young children whose 
inspiratory flow does not exceed the nebulizer driving flow. Attempts should 
be made to design nebulizer-facemask combinations that reduce exposure of 
the eyes and skin to aerosol while preserving efficiency of aerosol delivery to 
the lungs. 
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Abstract 
One-third of young children is distressed during inhalation therapy. It 
has been suggested that administration during sleep could be a good 
alternative for these children. A recent laboratory study in our department 
using an infant upper airway model showed significantly higher lung doses 
from a pMDI-spacer for sleep-breathing patterns compared with wake-
breathing patterns.  
Objective: We set up a daily life study to investigate the feasibility of 
aerosol administration by means of pMDI-spacer in sleeping young children. 
Design: During three weeks, 30 children (6-23 months old) with 
recurrent wheeze daily inhaled 1 puff of budesonide aerosol (Pulmicort® 200 
µg) while awake and 1 puff during sleep. Filters positioned between the 
NebuChamber® and facemask trapped the budesonide aerosol. Parents scored 
on diary cards the child’s asthma symptoms, degree of cooperation, and 
feasibility of administration.  
Results: In 69% of the sleep administrations the children woke up and 
75% of these cases the children were distressed. Mean filter dose (expressed 
as % of the nominal dose) while awake was 47% and during sleep 16% 
(p=0.007). Median within-subject dose variability while awake was 50% and 
during sleep 110% (p=0.007).  
Conclusion: Aerosol administration by means of pMDI-spacer during 
sleep offers no advantage and is not a feasible treatment option in most young 
children.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 |     109 
Introduction 
The pressured metered dose inhaler (pMDI) combined with a spacer is 
commonly used to deliver inhalation medication to infants and young 
children (1-4). However, the efficiency of drug delivery by pMDI-spacer is 
influenced by device-related and patient-related factors (1, 5-10). An 
important patient-related factor in young children is the highly variable 
breathing pattern, which is affected by the child’s level of cooperation (9-11). 
Cooperative young children with quiet tidal breathing have low breathing 
volumes and inspiratory flows. These children can efficiently clear the 
aerosol cloud from a small volume spacer, and generate relatively high lung 
depositions (3). Unfortunately, about 30% of young children are distressed 
during inhalation therapy (12, 13). When crying, they have high inspiratory 
flows and long pauses between breaths, resulting in low lung deposition and 
high oropharyngeal deposition (3, 9). Therefore, crying during the inhalation 
therapy is likely to reduce efficacy of the anti-asthma treatment.     
    
Administering the aerosol during sleep has been suggested to 
overcome cooperation problems in young children (10, 14, 15). Indeed, in a 
model study we found significantly higher lung doses for sleep-breathing 
patterns compared with wake-breathing patterns (14). However, the 
feasibility of aerosol administration during sleep in a daily life situation was 
never studied systematically. Therefore, we carried out a daily life study to 
investigate the feasibility of drug administration by means of pMDI-spacer in 
sleeping young children. 
Materials and methods 
Study population 
Thirty children aged between 6 and 23 months were recruited from the 
outpatient clinics of Erasmus MC-Sophia Children’s Hospital (Rotterdam, 
the Netherlands), St. Franciscus Gasthuis (Rotterdam, the Netherlands), 
Reinier de Graaf Gasthuis (Delft, the Netherlands), and Albert Schweitzer 
Ziekenhuis (Dordrecht, the Netherlands). They all had been treated with 
twice-daily inhalation therapy for recurrent wheeze for at least the previous 
month. Children with cardiac disease or another disorder that might affect 
lung function were excluded from the study. Written informed consent was 
obtained from all parents. The Ethics Review Committee of Erasmus MC 
Rotterdam approved the study. 
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Materials 
The metal NebuChamber® (250 ml, AstraZeneca, Sweden) in 
combination with the Galemed® (Galemed Corporation, Taiwan) facemask 
was used to administer 200 µg budesonide aerosol (Pulmicort® 200µg, 
AstraZeneca, Lund, Sweden) to the child. We used the Galemed mask – a 
round resuscitation mask with a thick and flexible rim– because it has been 
shown that use of this mask improved aerosol delivery compared with the 
pre-shaped NebuChamber facemask (13). Each child received a new 
budesonide pMDI, primed by shaking and firing 10 waste puffs. A filter 
(Marquest®, MQ303, USA) inserted between the spacer and the facemask 
trapped the aerosol inhaled from the spacer. The filter holders fitted tightly to 
the mouthpiece of the Nebuchamber. The filter holder of a Marquest filter 
added 38 ml of dead space. The pressure drop over the filter is 230 Pa at 60 
L·min-1 (1). 
Study design 
The study period encompassed three weeks, i.e. one run-in week 
followed by two actual test weeks. Over these three weeks, we visited the 
children four times at home. Parents were asked to follow standardized 
instructions on the use of inhalation therapy, as previously described by 
Janssens et al. (12). Efficiency of drug delivery was assessed by adding 
twice-daily one puff of budesonide aerosol to the child’s regular inhalation 
therapy, which was continued as before. Before each administration with 
study medication, parents placed a new filter between the NebuChamber and 
the mask to trap the budesonide aerosol. In the one-week run-in period, the 
parents practiced the study procedure with a placebo pMDI when the child 
was awake, and before regular inhalation therapy. In the mornings of weeks 2 
and 3, they administered one puff of budesonide aerosol before the child’s 
regular inhalation treatment, hereafter called “awake administration”. In the 
evenings of weeks 2 and 3, they administered the child’s regular inhalation 
treatment before the child went to bed. In addition, they administered one 
puff of budesonide aerosol after the child had fallen asleep, hereafter called 
“sleep administration” (Figure 1).  
 
To monitor asthma symptoms and cooperation, parents filled out a 
validated diary card after each administration procedure (12). The symptoms 
cough, wheeze and shortness of breath were each assigned a score ranging 
from 0 (no symptoms) to 4 (severe symptoms). The total asthma symptom 
score, with a maximum of 12, was defined as the sum of the scores for cough, 
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wheeze and shortness of breath. Cooperation during administration was 
assigned a score ranging from 0 (good cooperation) to 3 (fighting). 
 
In addition, parents addressed two questions about the “sleep 
administration” procedure. First: Did your child sleep throughout the 
administration procedure? Scores could range from 0 (slept through 
administration procedure), 1 (half-awake but tranquil), 2 (half-awake but 
distressed), 3 (fully awake but tranquil) and 4 (fully awake and distressed). 
Second: Was it easy to place the mask on the face? Scores could range from 0 
(impossible), 1 (possible, but extremely difficult), 2 (possible, but difficult) 
and 3 (possible without any problems). If parents rated 0, 1 or 2, they were 
asked to clarify why it was difficult to place the mask on the face, by marking 
one of the two options: A (child’s position in bed) or B (child’s restlessness).  
 
 
 
Figure 1. Aerosol administration in a sleeping young child. Failure to place the mask 
airtight on the face because of the position of the child in bed. 
 
Filter analysis 
All filters were analyzed in a blinded fashion by the Erasmus MC 
Hospital Pharmacy. The filters were washed with ethanol containing an 
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internal standard (fluocinolone acetonide). Budesonide amounts were 
measured by high performance liquid chromatography (HPLC), using an 
ethanol-water (43:57) mobile phase and a Supelcosil LC-18 column (5 µm 
particles, 5 * 0.46 cm (inner diameter)). Budesonide was detected by UV-
spectrophotometry at a wavelength of 254 nm. The method’s coefficient of 
variation was < 3%. 
Statistical analysis 
SPSS for Windows version 9.0 was used for statistical analyses. Filter 
dose, calculated as the amount of budesonide deposited on the filter, was 
expressed as a percentage of the nominal dose. Filter dose variability was 
expressed as the within-subject coefficient of variation (CV).  
 
Mean (± SD) filter doses and CVs were calculated for each child. To 
determine efficiency of administration during sleep, only filter doses and CVs 
of children sleeping throughout the administration procedure were compared, 
using Wilcoxon’s signed rank test.  
 
Mean total symptom scores and mean cooperation scores obtained 
from the weekly diary cards were compared using the Friedman test. A p-
value of ≤ 0.05 (two-sided) was considered to indicate significant differences. 
Results 
Thirty children (18 boys) entered the study. Results from three children 
were excluded from analysis because the parents had not complied with the 
protocol. Six children did not complete the third study week, because they 
were too distressed during the “sleep administration”. The missing data for 
these children were accounted for in the analysis. Twenty-one children fully 
completed the study. A total number of 350 and 331 filters were collected for 
the “awake administration” and “sleep administration”, respectively. Median 
(range) age was 15 (6-23) months. Mean symptom score (± SD) during the 
two actual study weeks was 1.4 (2.2).  
 
Figure 2 shows the mean filter dose (A) and the mean filter dose 
variability (B) for the “awake administration” and the “sleep administration”. 
Mean filter dose (± SD) for the “awake administration” was 47% (26) and 
that for the “sleep administration” 16% (13) (p=0.007).  
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Figure 2.  Part (a). Mean filter dose, expressed as % of the nominal dose, during the 
“awake administration” during the “sleep administration”, for those children who 
slept through the administration procedure.  ─── cooperative child and ----- 
uncooperative child during “awake administration”. Part (b). Mean filter dose 
variability (CV%) during the “awake administration” and during the “sleep 
administration”, for those children who slept through the administration procedure. 
─── cooperative child and ----- uncooperative child during “awake administration”. 
(a)
(b)
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Median filter dose variability (range) for the “awake administration” 
was 50% (21-198) and that for the “sleep administration” 110% (47-152) 
(p=0.007). 
 
Poor cooperation (score 2 or 3) was recorded in 29% of the “awake 
administration” procedures. In 69% of the “sleep administration” procedures 
the child woke up, and in 75% of these cases the children were distressed. 
Seven children showed poor cooperation during three or more “awake 
administration” procedures. These seven children slept in 47% of the “sleep 
administration” procedures. In three of them, the sleep dose was higher than 
the awake dose (Figure 2A).  
 
In 22% of the cases of children sleeping throughout the “sleep 
administration” procedure the parents reported mask-positioning problems. In 
96% this was caused by the child’s position in the bed, and in 4% by the 
child’s restlessness. 
Discussion 
The aim of our study was to investigate the feasibility of aerosol 
administration in sleeping young children in a daily life situation. 
Administration during sleep was found to be possible in no more than one-
third of the children. Moreover, filter doses of sleeping children were 
substantially lower than the filter doses obtained during the “awake 
administration”. 
 
Several studies have shown that inhalation therapy by means of pMDI-
spacer can be effective in the treatment of recurrent wheezing in young 
children (2, 3, 8, 16). However, up to 30% of the children below the age of 2 
years can not be treated effectively because they become distressed during 
the administration procedure (12, 13). Distress, with its problems in obtaining 
a good facemask seal and its high inspiratory flows during crying, results in 
low lung deposition (3, 9). Aerosol administration during sleep has been 
suggested to be an option to treat these uncooperative children (10, 14, 15). 
In a previous laboratory study we first recorded the breathing patterns of 18 
young children during sleep and while awake. Subsequently, an anatomically 
correct upper airway (SAINT-) model “inhaled” the drug with the recorded 
breathing patterns replayed by a computer-controlled breathing simulator. 
Lung dose was measured by placing a filter between the model and the 
breathing simulator. We found that the breathing patterns during sleep 
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resulted in significantly higher lung doses compared with the wake-breathing 
patterns (14).  
 
How can we explain the discrepancy between the findings from this 
laboratory study and from our daily life study? First, the laboratory study was 
performed under optimal conditions with an ensured airtight fit of the mask 
on the SAINT-model, whereas in our daily life study the airtight fit of the 
mask on the child’s face was not guaranteed. Fear of awaking the child may 
have withheld the parents to firmly press the mask on the child’s face. 
Furthermore, about one-fifth of the parents indicated that it was difficult to 
place the mask, either because the child’s position in bed or because of its 
restlessness. As shown in a previous study, even a tiny leak considerably 
reduces the amount of drug that can be inhaled from the spacer (17). 
Breathing patterns provide a second explanation for the discrepancy between 
the laboratory study and our daily life study. Breathing patterns used in the 
laboratory study were recorded prior to infant lung function testing while the 
children were awake and while they were sedated with chloralhydrate. We 
observed that the wake-breathing patterns were irregular and that the sleep-
breathing patterns were regular (14). Apparently, the sedated children had all 
been recorded during quiet, non-Rapid Eye Movement (REM) sleep (14). In 
contrast, in our daily life study aerosol therapy was administered when the 
children were in a deep natural sleep. It is possible that at time of aerosol 
administration the children were in a REM sleep. During REM sleep the 
breathing pattern is irregular with variable respiratory rate and tidal volume 
and frequent central apneas (18-20). Therefore, the breathing pattern during 
REM sleep is likely to result in low doses inhaled from the spacer (21, 22). 
 
Children who are uncooperative during inhalation therapy are the most 
important target group for aerosol administration during sleep. However, 
with this daily life study we demonstrate that the success rate of inhalation 
therapy during sleep is low, since most children woke up during the “sleep 
administration”.  Nevertheless, three of the seven uncooperative children 
obtained higher filter doses during “sleep administration” compared with  
“awake administration”. Moreover, two uncooperative children, who showed 
higher filter doses during the “awake administration”, had most likely been 
crying. In these children, filter doses are known to overestimate lung doses 
substantially (3, 9). Therefore, aerosol therapy during sleep could be 
appropriate in children who do not cooperate during the “awake 
administration” and remain asleep during the “sleep administration”. Hence, 
inhalation therapy during sleep can be attempted in uncooperative children, 
however, with little chance of success. 
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It should be noted that, in this study, the dose found on the filters 
represents the amount of aerosolised drug delivered to the patient. It does not 
provide information on clinical efficacy or lung deposition. However, the 
filter method was sufficient to investigate the feasibility of aerosol 
administration during sleep. 
 
In conclusion, many children were found to wake up when receiving 
aerosol therapy during sleep, and 75% of these cases the children were found 
to be distressed. In addition, in the children sleeping throughout the 
inhalation therapy filter doses were low and filter dose variability was high. 
Therefore, aerosol therapy by means of pMDI-spacer during sleep is not a 
feasible treatment option for most young children. Administration during 
sleep can be attempted in case of particularly uncooperative children. 
However, parents should be made aware that the success rate of inhalation 
therapy during sleep is low. 
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Abstract 
For optimal efficacy, anti-asthma drugs should be delivered to the 
desired region in the airways. To date, the optimal particle size for steroids in 
adults is not known.  
Objective: To evaluate the pulmonary bio-availability for inhaled 
beclomethasone dipropionate (BDP) aerosols of different particle sizes.  
Method: In a randomized single-blind cross-over trial, 10 mild 
asthmatic patients inhaled monodisperse BDP-aerosols of 1.5, 2.5 and 4.5 
µm. Gastro-intestinal absorption was blocked by activated charcoal. Plasma 
levels of 17-beclomethasone monopropionate (17-BMP) were measured 
through liquid chromatography plus mass spectrometry.  
Results: MMADs of 1.5 µm, 2.5 µm, and 4.5 µm gave mean 
maximum concentrations (Cmax) of 17-BMP of 475 pg·mL-1, 825 pg·mL-1, 
and 1300 pg·mL-1, respectively. The area under the curve (AUC) values of 
17-BMP for MMADs of 1.5 µm, 2.5 µm, and 4.5 µm were 2629 pg·h·mL-1, 
1161 pg·h·mL-1, and 2276 pg·h·mL-1, respectively. The mean terminal half-
time of 17-BMP for all three aerosol sizes was around 1.5 hr.  
Conclusions: Monodisperse BDP aerosols with a MMAD of 1.5 µm 
gave 2-3 fold lower values for Cmax and AUC than those with MMADs of 2.5 
and 4.5 µm. 
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Introduction  
For decades, the administration of medication via the inhaled route has 
been the mainstay of therapy for respiratory diseases such as asthma or cystic 
fibrosis (1-3). More recently, inhalation therapy was also introduced for 
diseases such as diabetes mellitus, where insulin is delivered via inhalation to 
obtain systemic effects lowering blood glucose levels (4-7). 
 
The efficacy of inhalation therapy – i.e. great beneficial effects and a 
low incidence of systemic side effects – largely depends on targeting a drug 
to the relevant regions in the lungs. Targeting is influenced by factors such as 
physiology, anatomy and pathology of the airways, breathing patterns, and 
the characteristics of the inhaled drug (8-14). Of these, the physiological, 
anatomical and pathological factors are hard to control. Breathing patterns, 
though, can be managed in theory, but in daily practice many flaws occur. 
However, it is the characteristics of the inhaled drug, such as particle size, 
that can be controlled effectively to enhance lung deposition.  
 
For mild and severely affected asthmatic adults bronchodilators with a 
MMAD of 2.8 µm were shown to give the best improvement in lung function 
and the least systemic side effects (15, 16).It is not known, however,  whether 
a MMAD of 2.8 µm is the most efficacious particle size for inhaled steroids 
in asthmatic adults. As the corticosteroid-receptor distribution is different 
from that of the β2-receptors, inhaled corticosteroids are likely to require a 
different deposition pattern (9). Clinical efficacy and systemic side effects of 
inhaled steroids should be measured to define the optimal particle size. 
Systemic side effects are elicited by systemic absorbed steroids. Hence, we 
conducted a pharmacokinetic study using monodisperse beclomethasone 
dipropionate (BDP) aerosols to investigate the pulmonary bio-availability as 
function of aerosol size in adults with mild asthma. Since BDP is rapidly and 
completely converted to 17- beclomethasone monopropionate (17-BMP), 
which is more potent than BDP, we focused on the 17-BMP 
pharmacokinetics. 
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Materials and Methods 
Study population 
Non-smoking men and women with stable mild asthma, between the 
ages of 18-60 years, were invited to participate. Subjects had to comply with 
the ATS-criteria for asthma (17), and their baseline forced expiratory volume 
in one second (FEV1) had to exceed 70% of the predicted value. Subjects had 
to show a reversibility of at least 9% of the predicted FEV1-value after 
administration of 200 µg salbutamol. Subjects were excluded if they had a 
secondary illness, pregnancy, and/or treatment that might interfere with a 
reaction to bronchodilators. All patients gave their written informed consent 
before the entry of the trial, which was approved by the hospital ethics 
committee. 
Study Design 
The study was designed as a randomized single-blind cross-over trial. 
Patients were studied at the lung function laboratory at the University 
Hospital Utrecht on three separate days with one-week intervals. Oral anti-
asthma medication was not allowed. Maintenance treatment with inhaled 
corticosteroids was discontinued 3 days prior to each study day. Long- and 
short-acting β2-mimetic agents were stopped respectively 15 and 8 hours 
prior to the start of the trial. The baseline FEV1 during each following session 
was not allowed to deviate more than 10% from that on day 1. Patients were 
first trained to inhale correctly. The inhalation maneuver consisted of a single 
inhalation from residual volume to total lung capacity with a constant flow of 
40-60 L/min, followed by a 10 seconds breath-holding period and 
subsequently a slow exhalation. A hot wire anemometer placed close to the 
patient’s mouth was used to measure inhaled volume and flow velocity. An 
indicator connected to the anemometer facilitated the patients to inhale at a 
constant flow. The amounts of aerosol deposited in the anemometer were 
negligible.  
Aerosol Generation 
In our experimental set-up (Figure 1), we used the 
electrohydrodynamic atomization (EHDA)-technique to generate 
Chapter 6 |     125 
monodisperse aerosols. This EHDA-technique has been extensively 
described by IJsebaert et al.(18). Monodisperse BDP-aerosols (geometric SD 
< 1.2) of different Mass Median Aerodynamic Diameters (MMADs) – 1.5 
µm, 2.5 µm and 4.5 µm – were generated from a BDP-ethanol solution. The 
generated monodisperse aerosols were collected in a large glass reservoir. 
Through an outlet at the end of the reservoir, part of the generated aerosols 
were sampled by an Aerodynamic Particle Sizer 33 (APS) (TSI, St. Paul, 
MN). The APS continuously measured particle size distribution and aerosol 
concentration (µg/l air) in the reservoir. Through another outlet patients 
inhaled 100 µg of the generated BDP-aerosols. The volume of inhaled air 
containing a dose of 100 µg BDP-aerosols was calculated by dividing this 
dose by the concentration of BDP-aerosols in the reservoir. As soon as the 
subjects had inhaled a dose of 100 µg BDP, they were switched over to 
ambient air to stop further inhalation of BDP-aerosols. 
 
 
 
Figure 1. Schematic representation of the experimental set-up 
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Blood sampling  
In order to be able to evaluate pulmonary bio-availability, 
gastrointestinal absorption was blocked by 5 grams activated charcoal prior 
to inhalation of the BDP-aerosols and 1, 2 and 4 hours after inhalation (19). 
An indwelling catheter (Becket Dickinson, Insythe W 18 gauge) was inserted 
into a forearm vein and a baseline blood sample was obtained. Consecutive 
blood samples were collected at 5, 10, 20, 30, 45, 60, 90, 120, 180, 240, 360 
and 420 minutes after inhalation. The first 2 ml of blood of each sample was 
discarded. After collection of the sample, the indwelling catheter was flushed 
with 4 ml of saline 0.9%. The blood samples were collected in lithium-
heparin tubes and immediately centrifuged in cooled centrifuges (7 ºC) for 10 
minutes at 2200 g. Plasma was harvested and the plasma samples were frozen 
at - 70 ˚C within 1 minute after harvesting. This protocol was designed to 
ensure correct 17-BMP measurements, as any conversion from BDP to 17-
BMP was instantly stopped.  
Pharmacokinetic Analysis 
Plasma concentrations of 17-BMP were analyzed using high 
performance liquid chromatography coupled simultaneously to a mass 
spectrometry (HPLC – MS-MS). 
 
Calibration standards, study and control samples were thawed at room 
temperature, mixed thoroughly and centrifuged again for 10 minutes at 2200 
g. Subsequently, the samples were extracted over a 50 mg C18 solid phase 
extraction (SPE) column. The SPE column was conditioned with 200 µl 
methanol (HPLC grade) followed by 400 µl water (Milli Q). Next, the 
column was loaded with a mix of 600 µl sample and 350 µl internal standard 
working solution. The eluate was dried under a stream of nitrogen at 40°C 
and reconstituted in 50 µl 40/60(v/v) acetonitrile/25 mM ammonium formate 
pH 5 buffer. 40 µl of the above-prepared sample was analyzed using a 
gradient elution on a 50 x 2.1 mm ODS3 5 µm column. The temperature of 
the column was kept on 40 °C at a flow rate of 0.8 ml/min.  
 
The conditions for the MS-MS were: split ratio: 1 in 4; 
ionisation/interface: TurboIonspray @ 450°C; scan mode: selected reaction 
monitoring (SRM); cycle time: 3.5 minutes. The following transitions were 
monitored for BDP and BMP-17, respectively: m/z 521 → m/z 319 and m/z 
527 → m/z 319.Data were acquired and processed using the software 
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package Analyst. LC-MS peaks were integrated and peak area ratios of 
BMP17 were calculated with respect to their internal standards. 
Statistics 
From the plasma concentration curves the following parameters were 
calculated:  
 
− AUC(0-t) = Area under the plasma concentration/time curve from 
zero to the last measured time point (t) via the linear trapezoidal 
rule;  
− AUC(0-∞) = Area under the plasma concentration/time curve from 
time zero extrapolated to infinity, calculated as AUC(0-t) + Clast/Kel.  
 
With the sampling scheme of this study being rather long, the plasma 
concentrations at the last measuring points were frequently below the limit of 
quantification (LOQ): these concentrations were set to 0. If the latter was the 
case, the AUC(0-∞) was not estimated and set equal to AUC(0-t); Cmax = 
Maximal concentration after inhalation; Kel = Apparent terminal elimination 
rate constant; T½ = Apparent terminal half-life. 
 
The statistical analysis was carried out according to current 
bioequivalence guidelines (20). Hence, the individual AUC(0-t),  AUC(0-∞) and 
Cmax data were log-transformed (natural logarithm) and subsequently 
analyzed using analysis of variance (ANOVA). The ANOVA model included 
subjects and aerosol sizes as main factors. The mean square error of the 
ANOVA was used to calculate the 90% confidence intervals of the AUC(0-t),  
AUC(0-∞) and Cmax ratios. 
Results 
Study population 
Ten mild asthmatic patients (of which 9 women) completed the trial. 
The average age (SD) was 46.6 (10.7) years. Mean FEV1 (SD) was 83.2 
(15.9) percent of the predicted value. No adverse events were reported. 
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Pharmacokinetics 
The mean plasma concentration/time profiles of 17-BMP for aerosols 
with MMADs of 1.5 µm, 2.5 µm, and 4.5 µm are shown in Figure 2. The 
derived pharmacokinetic parameters, i.e. ln-transformed AUC(0-t),  AUC(0-∞) 
and Cmax and the geometric mean bioavailabilities following all three 
inhalations are presented in Table 1. The pharmacokinetic comparison of the 
threemonodisperse aerosols is shown in Table 2. AUC and Cmax were 
significantly different between the 1.5 µm and the 2.5 µm aerosols (p<0.003) 
and between 1.5 µm and the 4.5 µm aerosols  (p<0.009). There was no 
significant difference in AUC and Cmax between the 2.5 µm aerosols and the 
4.5 µm aerosols. The 2.5 µm and 4.5 µm aerosols produced 2 to 3 fold higher 
serum levels at all sampling times compared with the1.5 µm aerosols.  
 
 
Figure 2. Mean plasma levels of 17 beclomethasone monopropionate (17-BMP) after 
inhalation of monodisperse aerosols with Mass Median Aerodyamic Diameters 
(MMAD) of 1.5 µm, 2.5 µm, and 4.5 µm. Gastrointestinal drug absorption was 
blocked by ingestion of charcoal. 
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In almost all patients, the highest concentrations of 17-BMP for the 1.5 
µm aerosols were seen at 10 minutes after inhalation and for the 2.5 µm and 
4.5 µm aerosols at 20 minutes after inhalation. Six hours after inhalation 17-
BMP was below the quantification limit in most patients. The median 
elimination half-life of 17-BMP was 1.5 hr for the 1.5 µm aerosols, 1.6 hr for 
the 2.5 µm aerosols and 1.4 hr for the 4.5 µm aerosols. 
 
Table 2 Comparisons between the pharmacokinetic parameters of beclomethasone 
17-monodipropionate for aerosols with MMAD 1.5 µm, 2.5µm and 4.5 µm.  
Comparison ( A versus B ) 
 1.5 µm vs 2.5 2.5 µm  vs 4.5 µm 1.5 µm  vs 4.5 µm 
LnAUC -2.933 0.223 -2.710 
90% CI for -4.415 to -1.451 -1.201 to 1.647 -4.192 to -1.227 
p value 0.003 0.788 0.005 
lnCmax (pg·mL-1) -0.779 0.208 -0.570 
90% CI for -1.116 to -0.441 -0.116 to 0.533 -0.908 to -0.233 
p value 0.001 0.279 0.009 
LnAUC: Ln-transformed area under the plasma concentration-time curve, LnCmax: Ln-
transformed maximum plasma concentration, CI: confidence interval   
Discussion 
The aim of this study was to investigate the pulmonary bio-availability 
of different monodisperse BDP aerosol sizes in adults with mild asthma. We 
found that AUC and Cmax were approximately 2-3 times lower for the 1.5 µm 
aerosols compared with the 2.5 µm and 4.5 µm aerosols.  
 
Monodisperse aerosols are useful to investigate the relationship 
between aerosol particle size and systemic availability, as aerosol distribution 
curves show minimal overlap. The drawback of this approach is the great 
effort required to generate monodisperse aerosols. In the present study we 
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used the EHDA method, which is a validated and consistent method to 
produce monodisperse BDP-aerosols (18). Besides, it is a relatively easy 
method compared with the spinning top generator, vibrating orifice or 
Sinclair-LaMer generators.  
 
For accurate charting of the systemic availability of monodisperse 
steroid aerosols as function of particle size, we controlled various factors that 
could affect lung deposition and lung dose. Firstly, patients inhaled the 
aerosol at a constant flow from a large volume glass reservoir, which acted 
like a spacer. Inhalation was followed by a 10 seconds breath-holding period. 
This procedure minimized oropharyngeal deposition and increased residence 
time, which in its turn enhanced deposition by sedimentation (21-24). 
Secondly, the concentration of aerosolized drug and the aerosol particle size 
in the glass reservoir were kept constant and were measured continuously by 
an aerodynamic particle sizer (APS). This minimized variations in inhaled 
dose between and within our patients, and between and within the different 
particle sizes. Thirdly, we controlled potential patient-factors by ensuring that 
the FEV1 at start of each visit was within 10% of the patients screening value. 
Fourthly, the gastro-intestinal absorption was blocked by activated charcoal 
to ensure that the systemic availability represented only the drug absorption 
through the lung. The method of assessing the systemic bioavailability of the 
active metabolite 17-BMP, after inhalation of BDP with the charcoal block 
method, was described and validated previously (19, 25). The kinetic 
parameters of 17-BMP found in our study, such as Tmax and T½, are within the 
range found in previous pharmacokinetic studies (19, 25, 26). With the 
methodology used in our study, differences in the measured kinetic 
parameters were unlikely to be biased by the above-discussed factors. 
 
The results of our study correspond to those presented by Heyder et al 
(27). In the latter, an in vivo-study with monodisperse aerosols, the alveolar 
deposition of particles between 2 and 6 µm was substantially higher than that 
of particles smaller than 2 µm. 
 
The greater systemic availability of the 2.5 µm and 4.5 µm particles 
compared with the1.5 µm particles can be explained by the inhalation 
technique employed in our study. The constant and deep inhalation followed 
by a breath-holding period, presumably allowed the 2.5 µm and 4.5 µm 
particles to bypass the extrathoracic airways and to penetrate into the 
conducting and peripheral airways in high doses. The deposition of these 
particles was favored by sedimentation during inhalation and the breath-
holding period. The 1.5 µm particles are typically able to pass through the 
extrathoracic and bronchial airways and to penetrate into the alveolar region. 
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However, a high proportion of these small particles will be exhaled again 
(27).  
 
The results of our study seem to be conflicting with the results of 
previous pharmacokinetic studies comparing hydrofluoroalkane-134 (HFA)-
BDP aerosols (MMAD 1.1 µm) with chlorofluorocarbon (CFC)-BDP 
aerosols (MMAD 3 µm). These studies showed that HFA-BDP yielded a 2-
times greater systemic availability compared with the same dose of CFC-
BDP (28, 29). This difference in systemic availability was explained by the 
smaller MMAD of the HFA-BDP compared with the CFC-BDP. However, 
differences in spray characteristics of the HFA- and CFC-pMDIs, as well as 
inhalation maneuver, were not considered to affect the results. A head-to-
head comparison between these studies and our study cannot be made, 
because HFA-BDP and CFC-BDP aerosols are polydisperse aerosols and we 
used monodisperse aerosols. Polydisperse aerosols are aerosols with a large 
particle size distribution. Therefore, it is not possible to assess the 
contribution of the various particle sizes on the systemic availability. Hence, 
the increased systemic availability found for the HFA-BDP aerosols might 
well be due to the increased deposition of both small and large particles of 
the HFA-BDP aerosol in the conducting and peripheral airways.  
 
Type of dispersity of the aerosol cannot solely explain the 
discrepancies in systemic availability between our study and the HFAs 
versus. CFCs studies (26, 28, 29). The HFA versus CFC studies followed a 
different study design. First, the HFA versus CFC studies did not use 
activated charcoal to block gastro-intestinal absorption and the systemic 
availability found in these studies, therefore, is a mixture of lung and GI-tract 
absorption (26, 28, 29). Second, the HFA versus CFC studies measured the 
first serum level of 17-BMP 0.5 to 1 hours after inhalation (26, 28, 29). 
However, as Cmax can be reached 10 minutes after inhalation (19),  the 
maximum concentration and a considerable part of the AUC might have been 
missed. Finally, one of the HFA-CFC studies measured the systemic 
availability via the beclomethasone plasma levels rather than the 17-BMP 
levels (29).  Beclomethasone, however, is only a small component of the 
systemic available substance compared with 17-BMP (19, 28).  
 
The goal of our study was to determine the systemic availability of 
inhaled corticosteroids with different aerosol particle sizes. The 1.5 µm 
aerosols gave a significant lower systemic availability compared with the 2.5 
µm and 4.5 µm aerosols. However, our data give only an indication of total 
lung deposition. They do not allow to draw conclusions about the distribution 
of deposition in the lung and about the clinical efficacy.  Furthermore, these 
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results obtained in adults are probably not applicable to young children. As 
children have narrower airways, the distribution of deposition in the airways, 
total deposition, and systemic availability will be different. To complete the 
definition of optimal aerosol particle size for inhaled corticosteroids in adults, 
clinical efficacy studies with monodisperse aerosols should be carried out. 
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Summary 
Inhalation is the customary method to deliver medication to patients 
with lung disease (1). Delivering medication directly to its site of action, 
inhalation therapy has the advantage of a more rapid therapeutic effect. 
Furthermore, less medication is needed to get the same therapeutic effect of 
systemically delivered medication (2-4). However, it is difficult to deliver 
aerosolized drugs to the lungs efficiently and in a reproducible manner, 
especially in young children. Efforts are made, therefore, to improve 
efficiency and efficacy of inhalation therapy in young children. These can 
only be successful if clinicians have knowledge of the basics of inhalation 
therapy (1, 3, 4).  
 
Chapter 1 of this thesis deals with the background of inhalation 
therapy. The major factors influencing efficiency and efficacy of inhalation 
therapy are presented, and radio-labeled and clinical efficacy studies in young 
children are reviewed. Finally, the aims of the studies presented in this thesis 
are discussed in detail. Mask seal, the child’s cooperation, and particle size 
seem to be critical factors affecting inhalation therapy in young children. As 
appeared from our literature review, mask seal and particle size have not yet 
been extensively studied. Furthermore, alternatives to administer aerosolized 
medication to the uncooperative child have not been studied in daily life. 
 
In chapter 2, we studied the effects of size and position of facemask 
leaks on spacer output and lung dose in-vitro, using an anatomically correct 
upper airway model of an infant (SAINT-model) and a computer-controlled 
breathing simulator. Spacer output and lung dose were measured from 
deposits on filters between spacer and facemask or between model and 
breathing simulator, respectively. We found efficiency of a pMDI-spacer-
facemask combination to be strongly related to leak size. Even a small air 
leak in the facemask can drastically reduce spacer output and lung dose. 
Spacer output was not related to leak position. However, lung dose for leaks 
near the chin was higher than that for leaks near the nose. The results of this 
study underline the importance of a perfect seal between mask and face when 
treating young children using a pMDI-spacer-facemask combination. 
 
Chapter 3 presents a four-week, randomized cross-over study in 
which we tested three commercially available facemasks in young children in 
daily life. The study aim was to examine how in young children facemask 
design affects the efficiency of aerosol delivery by means of pMDI-spacer. 
Spacer output was measured by placing a filter between spacer and facemask. 
The dose deposited on the filter represented the total dose delivered to the 
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patient. A round-shaped facemask gave significantly higher filter doses 
compared with face-shaped masks. We concluded that the efficiency of 
aerosol delivery to young children could be improved using a round 
facemask. However, many of the children were found to fight the therapy and 
did not easily accept any mask on the face. 
 
In Chapter 4, we evaluated patterns of aerosol loss from various 
facemasks combined with a nebulizer. In a randomized cross-over study, 
children under the age of 4 years were recorded on video while testing four 
different nebulizer-facemask combinations. Patterns of aerosol loss were then 
assessed from the video-recordings. The mask with large open vents showed 
the highest total aerosol loss and greater exposure of the children’s eyes and 
skin to aerosol compared with the other tested masks. We concluded, 
therefore, that masks with large vents are not suitable for nebulization 
therapy in young children. 
 
Chapter 5 presents a study in which we evaluated the feasibility of 
drug administration by means of pMDI-spacer in sleeping young children. 
Spacer output was measured by placing a filter between spacer and facemask. 
For two weeks, the children inhaled aerosol twice daily, once when awake 
and once when asleep. It appeared that during most sleep administrations the 
children woke up and became distressed. In addition, the dose inhaled when 
the child was asleep was significantly lower than when awake. Furthermore, 
the within-subject dose variability when asleep was significantly higher than 
that when awake. Therefore, we concluded that aerosol administration during 
sleep offers no advantage and is not a feasible treatment option in most young 
children.  
 
In Chapter 6 the pulmonary bio-availability for inhaled 
beclomethasone dipropionate (BDP) aerosols of different particle sizes was 
investigated. In a complex experimental set-up, we generated monodisperse 
BDP aerosols with three different mass median aerodynamic diameters 
(MMADs). Adults with mild asthma inhaled each of the three generated 
monodisperse aerosols on separate days. Subsequently, we obtained blood 
samples at multiple time-points after inhalation. For each aerosol size, plasma 
concentration-time curves were derived. We found that the systemic 
availability for monodisperse BDP aerosols with a MMAD of 1.5 µm was 2-3 
fold lower than for aerosols with MMADs of 2.5 and 4.5 µm.  
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General Discussion 
Inhalation therapy in young children is an extremely complex 
procedure. Its efficiency and efficacy are determined by many factors (see 
Chapter 1). From the studies presented in this thesis, we obtained more 
detailed knowledge about some of these factors. This section discusses the 
most relevant findings of this thesis. 
Facemask and pMDI-spacer 
Seal 
Our in-vitro study showed a strong negative correlation between leak 
size and lung dose. This result is especially important for aerosol therapy in 
young children, as many children under 2 years are uncooperative during 
inhalation therapy and may start crying. Crying children show high 
inspiratory flow rates, which enhance upper airway deposition and reduce 
lung dose (5). This, however, was not the only factor that reduced lung dose. 
If a child is uncooperative it is difficult to obtain a tight seal between mask 
and face, and leaks may then result. Our study revealed that even a small leak 
will drastically reduce lung dose.  
 
Design 
Facemask design is likely to play an important role in obtaining a good 
seal between mask and face. Therefore, we investigated how facemask design 
influences efficiency of aerosol delivery in daily life. The results of this study 
are consistent with aerosol therapy using a round-shaped facemask being 
more efficient compared with use of face-shaped facemasks. However, in 
children younger than 2 years patient-related factors, such as lack of 
cooperation, are probably more important than facemask design. This is 
confirmed by the results of our daily life study: uncooperative children had 
significantly lower filter doses for all masks. Furthermore, the differences in 
filter doses between the masks did not relate to cooperation. We conclude 
that, independent of the design of the mask, it is difficult to obtain a tight seal 
when the child is uncooperative. Furthermore, it is unlikely that facemask 
design influences the child’s cooperation. This may be explained by the 
following arguments: First, filter dose variability in our study increased 
significantly when a child did not cooperate, but there were no significant 
differences between the filter dose variability of the different masks. Second, 
cooperation scores for the masks did not differ. The problem remains, 
however, that many young children will resist having any mask pressed onto 
the face.  
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Facemask and nebulizer 
For nebulizers, the importance of a tight fitted facemask was shown by 
the results of an in-vitro study by Everard et al. When the nebulizer mask was 
moved 1 cm from the child’s face, the inspired dose of medication was found 
to be as low as 50% of the dose delivered when the mask was closely fitting 
to the face.  A 2 cm gap even resulted in 80% reduction of the dose delivered. 
Many nebulizers, however, have loose fitting masks with open vents. Thus, 
apart from reduced drug delivery, there may also be side effects from 
exposure of eyes and skin to aerosolized drug. When steroids are nebulized, a 
steroid rash may consequently develop over the face (6). In addition, there is 
a potential risk of cataract (6). An in-vitro study using radio-labeled aerosols 
found a variety of facial deposition patterns, depending on the nebulizer-
facemask combination (7). Facial deposition was significantly less when the 
facemask was vented, as vents allow the extra aerosol to easily exit the mask 
rather than to impact on the face. However, in children younger than 2 years 
relatively large amounts of aerosols can exit the nebulizer-facemask 
combination through the vents during inspiration and expiration. This 
phenomenon is due to the fact that their inspiratory flow rates often do not 
exceed the driving flow of the nebulizer (8). Our study in children aged 
between 7 months and 4 years confirmed that their eyes and skin were 
substantially exposed to aerosol when using the mask with large vents close 
to the face. Therefore, we concluded that masks with large vents are not 
suitable for young children. Incorporating vents in the nebulizer or 
positioning them between the nebulizer and the facemask can, probably 
overcome the problem of aerosol exiting the mask and impacting on the skin 
or in the eyes. The extra aerosol will then exit further from the face. 
Aerosol administration to uncooperative young children 
In about 30% of the aerosol administration procedures, young children 
are found to become distressed (9). Distress makes it difficult to obtain a 
good seal between facemask and face. In addition, high inspiratory flows 
during crying result in low lung deposition (5, 10). Therefore, distress during 
aerosol administration obviously reduces the efficiency and, consequently, 
the efficacy of the anti-asthma treatment. An option to avoid the unwanted 
results of distress would be to administer the aerosol to the sleeping child. 
Janssens et al. in an in-vitro study found that lung dose obtained with sleep-
breathing patterns was significantly higher than that obtained with wake-
breathing patterns (11). However, this concept was never tested in real life. 
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From our daily life study we conclude that administration during sleep is not 
a feasible treatment option in most young children, since many children woke 
up, showing signs of distress in 75% of the cases. In addition, children 
sleeping throughout the inhalation therapy had low filter doses and high filter 
dose variability. The discrepancy between the in-vitro study and our daily life 
study can be explained as follows. First, airtight fit of the mask on the face 
could be ensured in the in-vitro study, whereas in our daily life study airtight 
fit was not ensured. About one-fifth of the parents indicated that it was 
difficult to position the mask correctly, either due to the child’s position in 
bed or because of its restlessness. Furthermore, fear of awaking the child may 
have withheld the parents from firmly pressing the mask onto the child’s 
face. Our in-vitro study, described in Chapter 2 of this thesis, showed that 
even a small leak will considerably reduce the amount of drug that can be 
inhaled from the spacer. Hence, it is likely that the incomplete seal resulted in 
reduced aerosol delivery to the patient. A second explanation may lie in 
possibly different breathing patterns between the in-vitro study and our daily 
life study. In the latter, sleep breathing patterns were likely to be less regular, 
since aerosol was administered during a deep natural sleep. Hence, less 
aerosol could be drawn from the spacer. 
Particle size 
The efficacy of inhalation therapy largely depends on successfully 
targeting a drug to the relevant regions of the lungs. Targeting is influenced 
by several factors, such as physiology, anatomy and pathology of the 
airways, breathing patterns, and characteristics of the inhaled drug (5, 12-17). 
An effective and controllable factor to enhance targeting is the particle size of 
the inhaled drug. Previous studies in adults showed that the optimal particle 
size for a β2-agonist is 2.8 µm. For inhaled steroids, however, the optimal 
particle size is not known. It should be defined by investigating clinical 
efficacy and systemic side-effects for various particle sizes. We, therefore, 
studied pulmonary bio-availability as function of aerosol size using 
monodisperse aerosols. We found a higher systemic availability for the 2.5 
µm and 4.5 µm particles compared with the 1.5 µm particles. These results 
are in agreement with findings reported by Heyder et al. (18), and can be 
explained by the constant and deep inhalation technique employed in our 
study. Most likely, this technique allowed the 2.5 µm and 4.5 µm particles to 
bypass the upper airways and penetrate into the conducting and peripheral 
airways in high doses. Deposition of these particles in the conducting and 
peripheral airways was favored by sedimentation during the inhalation and 
breath-holding periods. The 1.5 µm particles are able to pass, in general, 
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through the extrathoracic and bronchial airways and to penetrate into the 
alveolar region. However, a high proportion of these small particles will be 
exhaled again (18). The findings from our study give information only on the 
systemic availability of three different monodisperse particle sizes. Reflecting 
the probability of systemic side effects, the systemic availability gives only 
an indication of total lung deposition. Therefore, conclusions about drug 
distribution in the airways and about clinical efficacy could not be drawn. 
 
Pharmacokinetic studies using monodisperse aerosols to investigate the 
pulmonary bio-availability as function of aerosol size in children would be 
very useful as well, seeing that they have smaller airways than adults. 
Deposition in children might take place in other sites, and thus total 
deposition and systemic availability may differ from those in adults. 
Unfortunately, the experimental set-up used in our study is not suitable for 
use in children. The major restricting factor is the impossibility of producing 
high concentrations of aerosolized drug in the reservoir. As a consequence, 
children cannot inhale a small dose of steroid in a single deep inhalation at a 
constant flow. With the maximum obtainable drug concentration, children 
would have to inhale at a constant flow for at least 7 to 10 minutes, which is 
physically impossible. Efforts should be made to find a suitable technique for 
such pharmacokinetic studies in children. 
Conclusions 
The design of the facemask, and consequently, the fit of the mask on 
the face, is an important determinant for the efficiency of aerosol delivery to 
children and for the occurrence of local side-effects. For use of the pMDI-
spacer combination, however, the child’s cooperation is probably even more 
important than facemask design. The alternative of aerosol administration 
during sleep is not feasible for very young children, as most of the children 
will wake up and become distressed. 
 
In adults, monodisperse aerosols with a MMAD of 1.5 µm gave lower 
systemic availability compared with aerosols with MMADs of 2.5 µm and 
4.5 µm. Pharmacokinetic studies using monodisperse aerosols are needed in 
children as well. 
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Future Directions 
In view of improving the efficiency of aerosol delivery by pMDI-
spacer combination in young children, future research should focus on ways 
of enhancing cooperation of the child during aerosol administration. There 
are several possibilities: 
 
• Developing a spacer with a child-friendly appearance; 
• Rewarding after completion of inhalation; 
• Implementing an introductory program for parents and children at the 
       start of the inhalation therapy to improve the acceptance rate; 
• Implementing an intensive follow-up program and coaching by a 
      qualified health-care worker. 
 
Aerosol delivery by means of nebulizers would benefit from facemask-
nebulizer combinations that reduce the amount of aerosol impacting on the 
eyes and skin of the patient but yet preserve the efficiency of aerosol delivery 
to the lung. Design efforts would have to focus, therefore, on positioning 
vents with a one-way valve in the nebulizer or connection piece at a greater 
distance from the face. 
 
For children, deposition patterns and systemic availability will most 
likely differ from those in adults, as children have smaller airway diameters 
and show other breathing patterns. To improve the efficacy of inhalation 
therapy in children – i.e. great beneficial effects and low incidence of 
systemic side effects, it is essential to determine optimal particle size for 
inhaled corticisteroid therapy in children. To this aim, a reliable technique of 
producing monodisperse aerosols that is feasible in children should be 
developed first. Subsequently, pharmacokinetic and clinical efficacy studies 
need to be carried out to define the optimal particle size for corticosteroids in 
children. 
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Samenvatting 
Inhalatietherapie wordt vaak gebruikt bij patienten met longziekten. 
Het voordeel van inhalatietherapie is dat de medicijnen direct op de plek 
terechtkomen waar ze nodig zijn. Hierdoor kunnen ze dus sneller effectief 
zijn. Bovendien is er minder medicijn nodig om hetzelfde effect te bereiken 
dan wanneer hetzelfde medicijn oraal en/of systemisch wordt toegediend. 
Echter, om het medicijn elke keer in de juiste hoeveelheid in de longen te 
krijgen, is, vooral voor kleine kinderen, erg moeilijk. Het is belangrijk dat, 
met name bij kleine kinderen de inhalatietherapie wordt geoptimaliseerd, 
zodat er vaker een constantere hoeveelheid medicijn in de longen komt. Om 
de inhalatietherapie te kunnen verbeteren is het essentieel om basiskennis te 
hebben. In hoofdstuk 1 van dit proefschrift komt de achtergrond van 
inhalatietherapie aan bod. De belangrijkste factoren die de efficiëntie en 
effectiviteit van inhalatietherapie beïnvloeden zijn uiteengezet. Verder wordt 
er een overzicht gegeven van klinische effectiviteit studies en studies met 
radio-gelabelde aërosolen in kleine kinderen. Als laatste worden de 
doeleinden van de studies die in dit proefschrift worden gepresenteerd 
besproken. 
 
De aansluiting van een masker op het gezicht, de coöperatie van het 
kind en de deeltjesgroottes van de aërosol zijn factoren die de 
inhalatietherapie aanzienlijk kunnen beïnvloeden. Uit de literatuur blijkt dat 
de aansluiting van het masker op het gezicht en de deeltjesgrootte niet 
grondig zijn onderzocht. Tevens zijn alternatieven voor inhalatietherapie bij 
het niet-coöperatieve kind  nog niet in de dagelijkse praktijk onderzocht. 
 
In hoofdstuk 2 wordt bekeken wat het effect is van de grootte en de 
positie van een lek in het masker op de dosisafgifte van een voorzetkamer en 
de hoeveelheid medicatie die in de longen komt (“longdosis”). Om dit te 
onderzoeken hebben we gebruikt gemaakt van een bovenste luchtweg model 
van een kind (SAINT-model) in combinatie met een ademhalingssimulator. 
Dosisafgifte en longdosis werden gemeten door middel van filters, die 
geplaatst werden tussen respectievelijk de voorzetkamer en het masker en 
tussen het model en de ademhalingssimulator. De studie toont aan dat de 
efficiëntie van een dosisaërosol (pMDI) in combinatie met een voorzetkamer 
en maskertje sterk afhankelijk is van de grootte van het lek in het masker. 
Zelfs een heel klein lek kan de dosisafgifte en de longdosis sterk doen 
verminderen. De dosisafgifte werd niet beïnvloed door de positie van het lek, 
echter de longdosis was hoger wanneer het lek bij de kin zat in vergelijking 
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tot een lek dichtbij de neus. De resultaten van deze studie benadrukken nog 
eens dat een goede aansluiting van het masker op het gezicht van essentieel 
belang is voor de efficiëntie van inhalatietherapie met een pMDI-
voorzetkamer. 
 
In hoofdstuk 3 wordt een gerandomiseerde cross-over studie 
beschreven waarin we de inhalatietherapie met behulp van een voorzetkamer 
gecombineerd met 3 verschillende maskertjes vergelijken bij kinderen onder 
de twee jaar in de thuissituatie. Het doel van deze studie was om de 
efficiëntie van de inhalatietherapie voor de verschillende maskertjes te 
onderzoeken door middel van het meten van de dosisafgifte van de 
voorzetkamer. De dosisafgifte werd gemeten door een filter te plaatsen tussen 
de voorzetkamer en het maskertje. De dosis op de filter was representatief 
voor de totale dosis die het kind zou hebben ingeademd als het filter er niet 
was geplaatst. Uit deze studie kwam naar voren dat het ronde maskertje een 
significant hogere dosisafgifte gaf in vergelijking met de gezichtsgevormde 
maskertjes. Wij concludeerden dat bij jonge kinderen de efficiëntie van 
inhalatietherapie met een metalen voorzetkamer verbeterd kan worden door 
gebruik te maken van dit ronde gezichtsmaskertje. Echter, een groot 
percentage (%) van de kleine kinderen was niet coöperatief tijdens de 
inhalatietherapie en accepteerde geen enkel maskertje op het gezicht. 
 
In hoofdstuk 4 hebben we het patroon van de aërosolwolk die tijdens 
het vernevelen ontsnapt ge-evalueerd voor 4 verschillende maskertjes 
gecombineerd met een vernevelaar. In een gerandomiseerde cross-over studie 
testten kinderen onder de 4 jaar vier verschillende masker-vernevelaar 
combinaties. De aërosolwolk die tijdens het vernevelen ontsnapte legden we 
vast op video. We konden uit deze studie concluderen dat de grootte van de 
aërosol wolk die ontsnapt over het algemeen meevalt. Het masker met grote 
ventilatiegaten liet echter een significant grotere aërosol wolk zien in 
vergelijking met de andere maskertjes. Wij concludeerden dat dit masker bij 
kleine kinderen wellicht een hoger risico op bijwerkingen voor ogen en huid 
kan geven dan de andere geteste maskers. Daarom is dit masker met grote 
ventilatiegaten minder geschikt voor verneveltherapie bij kleine kinderen. 
 
In oofdstuk 5 wordt een studie beschreven waarin we hebben 
gekeken of inhalatietherapie tijdens de slaap mogelijk was en een goed 
alternatief is voor niet-coöperatieve kinderen. De dosisafgifte werd gemeten 
door een filter te plaatsen tussen de voorzetkamer en het maskertje. De dosis 
op de filter was representatief voor de totale dosis die zou zijn ingeademd als 
het filter er niet was geplaatst. Elke proefpersoon kreeg twee weken lang 
twee keer per dag inhalatietherapie met studiemedicatie, één keer als hij/zij 
h
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wakker was en één keer tijdens de slaap. Het resultaat van deze studie was 
dat de meeste kinderen wakker werden als zij inhalatietherapie tijdens de 
slaap toegediend kregen. Bovendien werden de meeste kinderen ook nog 
onrustig en huilerig. Verder bleek dat de dosisafgifte tijdens de slaap-
toediening significant lager was dan tijdens de toediening als de patient 
wakker was. Ook de dosisvariabiliteit bleek significant hoger tijdens de 
slaap-toediening in vergelijking tot de toediening als de patient wakker was. 
Wij concludeerden dat inhalatie therapie tijdens de slaap voor  de meeste 
kleine kinderen geen voordelen biedt en geen goed alternatief is. 
  
In Hoofd tuk 6 wordt een studie beschreven waarin we de systemische 
beschikbaarheid van geïnhaleerde beclomethasone dipropionate (BDP)-
aërosolen in het bloed hebben gemeten. In een complexe opstelling maakten 
we monodisperse BDP-aërosolen met 3 verschillende mass median 
aerodynamic diameters (MMADs). Volwassenen met mild astma inhaleerden 
de drie verschillende monodisperse aërosolen op verschillende studiedagen. 
Gastro-intestinale opname van BDP werd geblokkeerd door tevoren actief 
kool (Norit) toe te dienen. Bloedmonsters werden genomen op verschillende 
tijdstippen na inhalatie. Voor elk deeltjesgrootte kon vervolgens de 
plasmaconcentratie curve in de tijd worden uitgezet. Wij vonden dat de 
systemisch beschikbaarheid voor monodisperse BDP-aërosolen met een 
MMAD van 1.5 µm 2-3 keer lager was dan de systemische beschikbaarheid 
voor monodisperse BDP aërosolen met een MMAD van 2.5 en 4.5 µm. 
 
Conclusies 
Voor efficiënte inhalatietherapie met een pMDI-voorzetkamer bij 
kleine kinderen is een goed passend gezichtsmaskertje erg belangrijk. De 
coöperatie van het kind lijkt echter nog de meest bepalende factor voor de 
efficiëntie van de inhalatietherapie. Verder bleek inhalatietherapie tijdens 
slaap geen goed alternatief voor het niet-coöperatieve kind.  
 
Om bij verneveltherapie het risico op mogelijke locale bijwerkingen 
van huid en ogen te verlagen is het aan te bevelen om een goed passend 
maskertje te gebruiken met kleine ventilatiegaten in de vernevelaar of tussen 
masker en vernevelaar, zodat overtollig aërosol op enige afstand van het 
gezicht het systeem kan verlaten. 
 
In de zoektocht naar het meest effectieve deeltjesgrootte voor inhalatie 
van corticosteroïden blijkt dat bij volwassenen met mild astma aërosolen met 
een MMAD van 1.5 µm een lagere systemische beschikbaarheid geven in 
vergelijking tot aërosolen met MMAD van 2.5 µm en 4.5 µm. Klinische 
effectiviteits studies met aërosolen van verschillende MMADs zouden 
s
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uitgevoerd moeten worden om te kijken welk deeltjesgrootte klinisch het 
meest effectief is. Dan pas is de optimale deeltjesgrootte te bepalen. Omdat 
kinderen geen kleine volwassenen zijn, ligt het in de verwachting dat 
effectieve inhalatietherapie bij kinderen een andere deeltjesgrootte vereist. 
Voor het verbeteren van inhalatietherapie bij kinderen zijn studies naar de 
meest effectieve deeltjesgrootte daarom ook bij kinderen nodig. 
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afsluitend woord. Tijdens mijn studie geneeskunde en AGNIO-schap had ik 
nooit gedacht dat ik ooit zou gaan promoveren. Hoogzwanger van Anna 
Maria kreeg ik plotseling een telefoontje uit Rotterdam dat er een potje met 
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jaren achter de rug met de Pulmo-afdeling. Soms lijkt het net wel een 
kippenhok. Gelukkig weet je je hoofd altijd koel te houden. Bedankt voor de 
mogelijkheid om onderzoek te doen op jouw afdeling, je snelle correcties en 
je kritische blik. 
 
Dr. H.A.W.M Tiddens, beste Harm, jij bent degene die aan de basis 
van dit onderzoek staat. Had je me nu bijna 6 jaar geleden gebeld omdat die 
Italiaanse naam je aansprak? Ik ben je in ieder geval dankbaar dat je me de 
mogelijkheid hebt gegeven om onderzoek met jou te doen. Hettie zei eens dat 
jij een onuitputtelijke bron van energie en ideeën bent. Ik kan me daar alleen 
maar bij aansluiten, en hopen dat dit nog lange tijd zo blijft. Dit in combinatie 
met je commerciële kwaliteiten zal nog veel mooi onderzoek op de pulmo-
afdeling mogelijk maken. Als je nog eens een potje met geld over hebt, moet 
je maar bellen...... 
 
Dr. P. Zanen, beste Pieter, een bijzonder woord van dank naar jou. 
Zonder enige twijfel gaf je mij de mogelijkheid om samen met jou het 
monodisperse aërosolen onderzoek af te ronden. Hierdoor kon ik mijn 
proefschrift compleet maken. Bedankt voor je prettige samenwerking, je 
laagdrempeligheid, en je droge humor. Je bent onvoorstelbaar “easy going”. 
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Prof.dr. Vulto, Prof.dr. Frijlink, Prof.dr. van der Heijden, wil ik graag 
bedanken voor de bereidheid om in de kleine commissie zitting te nemen en 
voor de beoordeling van dit manuscript. Prof.dr. van Aalderen en dr. 
Duiverman dank ik voor hun deelname aan de grote commissie. Dr. de Boer 
wil ik ook bedanken voor zijn bereidheid deel te nemen aan de oppositie. 
 
Het onderzoek was niet mogelijk geweest zonder financiële steun van 
AstraZeneca, Nederland. Ik wil AstraZeneca graag bedanken voor de 
volledige sponsoring van dit onderzoek en jullie bijdrage aan de drukkosten 
van het proefschrift. Graag wil ik Marjo Tieleman en Joke Eggermont 
speciaal bedanken voor hun betrokkenheid en ondersteuning tijdens de 
afgelopen jaren. Het laatste stukje van het promotie-traject zijn jullie allebei 
naar de oncologie-research unit geswitched, ik wens jullie daar veel succes 
toe. 
 
Mijn paranimfen, Tessa Pasmooij en Els van der Wiel. Lieve Tes,  je 
bent een geweldig mens. Ik bewonder je voor je kracht, je doorzettings-
vermogen, je organisatorische talenten en je grensoverschrijdende vriend-
schap. Bedankt voor al je steun, gezelligheid en vriendschap in de afgelopen 
jaren. Je bent als een zus voor me. Lieve Els, daar sta je dan, beloofd is 
beloofd. Die belofte was natuurlijk niet zomaar gedaan. Je bent een super-
mens en ik vond het geweldig om met jou een kamer te delen. De 
uiteenlopende koffie-gesprekken heb ik het afgelopen jaar helaas al moeten 
missen. Bedankt voor al je support, je altijd luisterend oor, je eerlijke mening, 
opbouwende kritiek, gezellige congres-uitjes en inspirerend enthousiasme.  
 
Graag wil ik alle ouders en kinderen die de afgelopen jaren hebben 
meegedaan aan de verschillende studies bedanken voor hun deelname. 
 
Bahar Ates, als studente kwam je mij ondersteunen in een paar van 
mijn onderzoeken. Heel wat kilometers hebben wij samen in de auto gezeten. 
Bedankt voor je hulp en je gezelligheid en heel veel succes in je loopbaan als 
dokter! 
 
Graag wil ik het hele Pulmo-team bedanken, dat in de afgelopen jaren 
ook aardig in samenstelling is veranderd. Hopelijk is het mij vergeven als ik 
iemand vergeten ben: Mariëlle Pijnenburg, Peter Merkus, Annemie Boehmer, 
Ward Hofhuis, Carmelo Gabriele, Jeroen Hol, Laurens Koopman, Pim de 
Jong, Ruben Boogaart, Eveline Nieuwhof, Tjitske v/d Zande, Sonja Phaff, 
Merel van Pieterson, Aafke, Anne, Astrid, Edith, Monique, Saskia, Sylvia, 
Annelies, Elvira, Margriet, Marianne, Marion, Maaike, Sandra. Karen 
Corver, allebei komen we uit het hoge noorden. Je bent een lieve en gezellige 
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kamergenote, die zichzelf vaak wegcijfert. Heel veel succes in het Engelse en 
hopefully we will keep in touch! Een speciaal woord van dank wil ik richten 
tot dr. H. Janssens, beste Hettie, bedankt voor de tijd die je voor mij vrij 
wilde maken in de voor jou zo hectisch laatste maanden van je promotie-
onderzoek. Irma Beckers, wat moet de afdeling zonder jou?? Mensen 
vergeten vaak dat aan de basis van een goedlopende afdeling een kanjer van 
een secretaresse staat. Dank voor al je hulp! 
 
De AIO-groep is enorm groot in het Sophia, en er zijn het afgelopen 
jaren heel wat collega’s nieuw bijgekomen of gepromoveerd. Een aantal wil 
ik in het bijzonder bedanken voor de gezelligheid tijdens koffie pauzes, 
lunches, borrels, kerstdiners en uitjes: Marinka, Jolt, Itse, Mandy, Floor, 
Gwenda, Pieter, Edwin, Clementien, Linda (HIV-vpk), Carmelo, Ward, 
Daphne, Saskia, Laurens en Hettie. 
 
Dr. W.C.J. Hop, beste Wim. Ik geloof dat ik de enige ben met wie je 
zonder sigaret de berekingen van de verschillende studies hebt uitgevoerd. Ik 
waardeer en respecteer dat enorm! Bedankt voor al je hulp bij de statistiek! 
 
Frans van Vliet, ik ben je erg dankbaar voor het precieze werk dat je 
verricht hebt voor het analyseren van al mijn filters. Super! 
 
Dr. L. Ruijgrok, beste Liesbeth, we waren aardig op weg met de 
monodisperse studie, helaas is het er niet meer van gekomen. Bedankt voor je 
prettige samenwerking, en voor de gezelligheid op congres. 
 
Dr. A.F.M. Verbraak, beste Ton, hartelijk dank voor het beschikbaar 
stellen van jouw longsimulator en je hulp bij het gebruik ervan. Ik vond het 
erg gezellig bij je op jouw afdeling.  
 
De mensen van de Centrale Instrumentele Dienst (CID) wil ik 
bedanken voor het meedenken met de verschillende studies en het maken van 
onderdelen voor experimentele set-ups. 
 
Kees Geerse, jij hebt me nog wat meer wegwijs gemaakt in de wereld 
van de aërosolen. Ik vond het erg leuk om bij je op de TU Delft te komen 
kijken en ik ben je dankbaar voor je hulp in de voorbereiding van met name 
de “film-studie”.  
 
Voor het recruteren van patiënten is hulp van kinderartsen in de 
perifere klinieken onmisbaar. Ik wil dr. R. Schornagel, dr. P.J.C. van der 
Straaten, en dr. N. dan de Lely en hun team kinderartsen uit het Albert 
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Schweitzer Ziekenhuis in Dordrecht en de Reinier de Graaf Groep in Delft 
bedanken voor het recruteren van patiënten. Een speciaal woord van dank 
naar: Dr. H. IJsselstijn, toen nog werkzaam in het St. Franciscus in 
Rotterdam, beste Hanneke, door jouw inzet konden vele kinderen worden 
geïncludeerd in de slaap-studie, bedankt!  
 
Lieve Maaike Sikma, we hebben allebei erg drukke levens, en wonen 
niet naast elkanders deur, maar ik weet dat je er altijd voor mij zult zijn. Ik 
hoop dat jij ook weet dat ik er altijd voor jou zal zijn! 
 
Mijn lieve prinsesjes, Anna Maria, Christina en Elena, jullie zijn de 
parels in mijn leven en hebben voor altijd een heel speciaal plekje in mijn 
hart! Mama’s boekje is eindelijk af en we gaan nu dat feestje vieren! Anna 
Maria en Christina, ik vond het geweldig om met jullie te swingen op K3 in 
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bent onze lieve, ondeugende zonnestraaltje! Ragazze, vi voglio molto, molto 
bene, per sempre! 
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you did the complete lay-out of this book. We sat evening and evening 
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acknowledged! It hasn’t been really easy for us, especially during the past 
year. You are the little crazy Italian man of my life, and remember, we make 
a beautiful team! Let’s be grateful for our three wonderful daughters and let’s 
enjoy life together! Grazie e ti amo! 
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